Global DTx reimbursement explorer

1 Minute pour mon Coeur is a remote-monitoring / digital health platform, developed by Newcard, used for chronic heart failure remote monitoring. Physiological parameters (weight, blood pressure, heart rate) collected via a patient kit and reviewed by the treating care team. It is reimbursed nationally in Belgium.

6 additional Hainan Class II-approved DTx products (#1-3 pre-Feb-2024, #8-11 during 2025 -- not individually named or dated in this pass) is a digital therapeutic (DTx), used for aggregate reference row. Hainan's provincial regulator had approved 11 DTx products under its Class II fast-track as of its own Nov 2025 press release (up from the 10-product Aug 2025 trade-press figure used elsewhere in this tab); this row stands in for the 6 beyond the 5 named/dated above (Xinjing plus approvals #4-7), spanning chronic-disease management, psychiatric/cognitive, ophthalmology, oncology and...

Abbott Merlin.net is a connected medical device (with companion software), developed by Abbott Laboratories (legacy St. Jude Medical), used for pacemaker / ICD / CRT follow-up. It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since 1 April 2016.

Abbott Merlin.net is the remote-monitoring platform through which recordings from the manufacturer’s implanted cardiac devices reach the treating cardiology team between in-person checks. France reimburses the implantable-cardiac-monitor follow-up activity through a product-specific code per platform, all at an identical rate; the clinical service is the same across vendors and the French tariff reflects that.

Ongoing

actensio is a digital therapeutic (DTx), developed by mementor DE GmbH (same manufacturer as the still-active DiGA 'somnio'), used for hypertension (high blood pressure). It is available in Germany on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

N/A (delisted); self-pay commercial pricing was quoted per 90 days

ACTICORE1 is a digital therapeutic (DTx), developed by ACTICORE AG (Basel, Switzerland), used for stress urinary incontinence (ICD-10 N39.3). It consists of a pelvic-floor pressure sensor (hardware, placed under the patient rather than inserted) connected via Bluetooth to a companion app that runs a biofeedback-based pelvic-floor training programme. It is reimbursed nationally in Germany via the DiGA Sec.139e SGB V pathway, provisionally listed (Erprobungszeitraum 16 Sep 2026 - 15 Sep 2027). Manufacturer price EUR 795.00, includes the sensor hardware; no contracted-physician service required; available in German only.

ActiveTEP (Hüfte / Knie) is a digital therapeutic (DTx), developed by DORA Digitale Orthopädie Anwendungen GmbH (Leipzig); part of the EU-co-funded 'Health Labs4Value' research project, also co-financed by the Free State of Saxony, used for total hip replacement (ActiveTEP Hüfte) and total knee replacement (ActiveTEP Knie). 24-week companion (12 weeks pre-op + 12 weeks post-op): 60+ knowledge modules, training plans, diary/progress tracking; the knee version followed the hip version to market. It is reimbursed in Germany through regional or insurer-specific contracts rather than a...

24 weeks (12 weeks pre-op + 12 weeks post-op)

Ahead Health is a digital prevention programme, developed by Ahead Health AG, used for early detection of cancer, cardiovascular disease and other conditions via preventive full-body screening. Not indication-specific. It is offered in Switzerland as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Allara Health is a virtual women's health clinic focused on PCOS and related hormonal and metabolic conditions, combining clinician visits with dietitian support, prescriptions and supplements. The company names its in-network payers rather than claiming blanket coverage, and states the coverage is state-by-state: Aetna (including Meritain), Blue Cross Blue Shield (including Anthem, CareFirst and affiliated plans), Cigna, UnitedHealthcare (including Oxford and UMR) and GEHA. Where a plan is not in network it offers a paid membership instead. Even with in-network coverage, patients remain responsible for copayments, coinsurance and deductibles. Checked Oct 2026.

Ongoing

Alvie is a digital therapeutic (DTx), developed by Anker Health GmbH (Bayreuth, Germany, founded 2022), used for nonspecific pain of the cervical, thoracic and lumbar spine (ICD-10 M54). A CE-marked Class I medical device delivering an algorithm-personalised daily exercise plan plus pain education and relaxation content, adapted to the user's self-reported pain level. It is currently available in Germany only on a self-pay basis (EUR 135 for a 90-day licence, introductory price) while the company pursues DiGA (Sec.139e SGB V) listing; Alvie has already obtained BSI TR-03161 certification (the DiGA cybersecurity/IT-security requirement) without conditions, and a completed two-arm RCT (BackCare, DRKS00036874, n=143) is awaiting publication. Once listed as a DiGA, the manufacturer expects a price of roughly EUR 220-240, reimbursable by statutory health insurance.

90-day self-pay licence; 12-week programme

AnyHand (LIME medical) is a connected medical device (with companion software), developed by LIME medical GmbH, used for post-injury hand/finger rehabilitation aftercare (bone, tendon, ligament injuries). Robotic-assisted motion therapy. It is reimbursed in Germany case-by-case through statutory accident insurance.

attexis - digitale Therapie bei ADHS im Erwachsenenalter is a digital therapeutic (DTx), developed by GAIA AG, used for ADHD (adults). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA §139e SGB V; manufacturer price EUR599.40/90-day Rx (diga.bfarm.de).

Axia - für axiale Spondyloarthritis (axSpA) is a digital therapeutic (DTx), developed by Applimeda GmbH, used for axial spondyloarthritis. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR599.00/90-day Rx (diga-verzeichnis.de).

Axomove Therapy is a digital rehabilitation and telemonitoring platform, developed by Axomove SAS, used for chronic/subacute low back pain rehabilitation follow-up after hospital-based functional rehabilitation. It is reimbursed nationally in France via the PECAN/LATM pathway. PECAN favourable CNEDiMTS/HAS opinion 22 Oct 2024; favourable CNEDiMTS/HAS opinion for permanent LATM listing published 7 May 2026 -- first PECAN-origin musculoskeletal/rehabilitation product to reach durable reimbursement.

bauchgefuehl is a digital prevention programme, developed by bauchgefuehl, used for online course on gut health and digestion (Darmgesundheit). It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifiziert nach Sec.20 SGB V; bis zu 100% Zuschuss der gesetzlichen Krankenkasse.

Beating the Blues is a digital therapeutic (DTx), used for depression and generalised anxiety disorder (GAD). Its earlier NICE guidance (TA97) was withdrawn in 2018. It was named in NICE's 2023 draft process for a new depression/anxiety Early Value Assessment pathway, but does not appear in either of the resulting final guidances (HTG675 for depression, HTG676 for anxiety) -- unlike SilverCloud, Koa Health's iCT-PTSD/iCT-SAD and Spring, which are named in those final guidances. No active NICE backing for this product was found as of this research.

BeWell Well@Home is a remote-monitoring / digital health platform, developed by BeWell Innovations, used for chronic heart failure remote monitoring. Questionnaires, connected vital-sign measurement, education, diary, secure messaging and video consultation with the care team. It is reimbursed nationally in Belgium.

BIOTRONIK Home Monitoring is a connected medical device (with companion software), developed by BIOTRONIK SE & Co. KG, used for pacemaker / ICD / CRT follow-up (cardiac implantable electronic devices). It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since 1 April 2016.

Biotronik Home Monitoring Service Center is the remote-monitoring platform through which recordings from the manufacturer’s implanted cardiac devices reach the treating cardiology team between in-person checks. France reimburses the implantable-cardiac-monitor follow-up activity through a product-specific code per platform, all at an identical rate; the clinical service is the same across vendors and the French tariff reflects that.

Ongoing

BlueStar is an FDA-cleared digital therapeutic, developed by Welldoc, Inc. (Columbia, MD), used for type 1 and type 2 diabetes management. One of the earliest FDA-cleared DTx products (original clearance 2013, with 10+ subsequent clearances), it combines a patient-facing coaching app with connected glucose-meter/CGM data for the prescribing clinician. It is reimbursed today primarily through Medicare and commercial Remote Patient Monitoring billing (CPT 99453/99454/99457), billed by the treating clinician -- a different code family from the Medicare DMHT G-codes used by behavioral-health digital therapeutics -- and is also distributed via employer and health-plan contracts.

Ongoing chronic-care management

Boston Scientific LATITUDE Clarity is a remote-monitoring data-management system for the LUX-Dx insertable cardiac monitor (ICM), developed by Boston Scientific Corporation, used for remote monitoring and programming of patients with an implantable cardiac monitor. It is reimbursed nationally in France via the LATM telemonitoring pathway. Listed on France's LATM list via Arrete du 3 mars 2026, for remote monitoring of LUX-Dx ICM patients.

Boston Scientific LATITUDE NXT is a connected medical device (with companion software), developed by Boston Scientific Corporation, used for pacemaker / ICD / CRT follow-up. It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since 1 April 2016.

Breathment is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, used for COPD (also asthma). AI-guided breathing/stretching/mobilisation exercises via phone camera with live audio/visual form feedback, plus a physiotherapist-staffed chat/video-consultation layer (app + human hybrid, not software-only). It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

3, 6, or 12 months (tiered -- EUR100/EUR200/EUR400 respectively)

brite (XO Life, formerly ImpactMonitor) is a manufacturer-sponsored digital therapy-support platform, developed by XO Life GmbH (Munich, Germany), used for asthma and COPD digital therapy support funded via a biosyn partnership, alongside a broader medication-adherence and side-effect-tracking service spanning 30+ condition areas with various pharmaceutical partners. Unlike this dataset's other entries, funding comes from the drug/device manufacturer paying XO Life directly, rather than a statutory health insurer or employer.

Calorymama Plus (Karo Mama Purasu) is a digital prevention programme, developed by Wellmira Inc. / Link and Communication Co., Ltd., used for general nutrition, exercise and sleep health management via AI photo-based food logging. Not indication-specific. It is offered in Japan as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Cara Care für Reizdarm is a digital therapeutic (DTx), developed by HiDoc Technologies GmbH, used for irritable bowel syndrome. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR248.00/90-day Rx (diga-verzeichnis.de).

CardioSignal is a CE Class IIa-certified digital health monitoring app, developed by Precordior Oy (Turku, Finland), used for atrial fibrillation detection via a 60-second smartphone-based chest measurement using the phone's accelerometer and gyroscope. It is sold self-pay direct-to-consumer in 15+ countries. Precordior is separately one of 10 companies selected for Finland's DigiFinland pilot (Oct 2025), a government evaluation programme testing how digital therapies should integrate into the healthcare system -- the pilot itself carries no reimbursement mechanism yet.

60-second measurement

Careline Solutions is a French telemonitoring provider for chronic heart failure, working as a Medtronic partner. Patients are followed remotely between consultations and signals of deterioration are relayed to the cardiology team. Unlike Satelia Cardio, which holds its own higher-rated code for the same condition, Careline is reimbursed through the generic heart-failure telemonitoring activity -- a reminder that in France a reimbursed service does not always mean a separately listed product.

CareLink System is a remote-monitoring / digital health platform, developed by Medtronic Belgium (Medtronic plc), used for pacemaker / ICD / CRT-D / CRT-P follow-up (cardiac implantable electronic devices), via the MyCareLink Heart app or a bedside monitor. It is reimbursed nationally in Belgium.

Caspar Health (digitale Reha-Nachsorge) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Caspar Health GmbH, used for general post-rehabilitation aftercare (multi-indication). Structured digital follow-on care after orthopaedic, cardiac, oncological, psychosomatic and other rehab stays, intended to sustain therapy gains after discharge. It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Not fixed (duration tied to individual DRV aftercare period)

Caterna Vision is a digital therapeutic (DTx), developed by Caterna Vision GmbH (Berlin), used for amblyopia ('lazy eye'), children aged 4-12. Online vision-training games using a background wave pattern intended to stimulate the brain-eye connection, ~30-45 min/day, ophthalmologists can monitor progress online. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

3 months (fixed therapy period)

Champion Health is a digital prevention programme, developed by Champion Health Ltd., used for mental health and musculoskeletal risk, plus physical and financial wellbeing. Not indication-specific. It is offered in the United Kingdom as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

CodeThera is a digital therapeutic (DTx), developed by EmocoG (이모코크), used for mild cognitive impairment (MCI). It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

Cogthera App is a digital therapeutic (DTx), developed by Cogthera GmbH (Munich, Germany), used for mild cognitive impairment (MCI, ICD-10 F06.7) and mild Alzheimer's dementia. A personalised multimodal intervention combining cognitive training, dual-task movement exercises, audio-guided meditation and educational content. Cogthera GmbH states it is provisionally listed as a DiGA and reimbursed by statutory health insurance; a CE-marked Class I medical device since December 2023. However, Cogthera App does not appear anywhere in BfArM's official DiGA-Verzeichnis as of this research (checked including the delisted/"Gestrichen" filter), so the DiGA-listing claim could not be independently verified. Cogthera GmbH reports that a multicenter randomized controlled trial in Germany showed positive effects on cognitive ability in people with MCI; this has not been published, so the claim could not be independently verified.

Comarch HomeHealth 2.0 is a remote-monitoring / digital health platform, developed by Comarch AG - Belgian Branch, used for chronic heart failure and other chronic-disease remote monitoring. It is reimbursed nationally in Belgium.

companion patella powered by medi is a digital therapeutic (DTx), developed by medi GmbH & Co. KG, used for patellar conditions / knee pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR223.49/90-day Rx (diga.bfarm.de).

companion(R) shoulder is a digital therapeutic (DTx), developed by medi GmbH & Co. KG, used for shoulder lesions/pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR419.00/90-day Rx (diga.bfarm.de).

Comunicare is a remote-monitoring / digital health platform, developed by Comunicare, used for cardiac & renal remote monitoring. It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

Comunicare is a remote-monitoring / digital health platform, developed by Comunicare Solutions, used for chronic-disease communication and self-management. Cancer, heart failure, COPD, multiple myeloma and other chronic conditions (multi-indication digital care companion, not heart-failure-specific). It is reimbursed nationally in Belgium.

Cordiva is a digital therapeutic, developed by CDM e-Health, used for remote home monitoring of chronic heart failure patients -- symptom questionnaire plus connected weighing scale, with alerts to the care team. A 2016 CNEDiMTS opinion did not recommend Cordiva for standard LPP listing, citing insufficient/non-transposable evidence of therapeutic benefit.

CoreHealth (now CoreHealth by Carebook) is a digital prevention programme, developed by CoreHealth Technologies Inc., used for general corporate wellness programme administration. Flexible/white-label, not indication-specific. It is offered in Canada as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

CorinRPM (Corin -- Connected Orthopaedic Insight) is a remote-monitoring / digital health platform, developed by Corin Group (Corin Limited), used for hip and knee replacement (joint arthroplasty) perioperative patient engagement, PROMs collection, and progressive post-op exercise videos, feeding the surgeon-facing CorinConnect analytics platform. It is provided free in the United Kingdom by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any insurer, employer or the patient.

Curable is a direct-to-consumer mobile app, developed by Curable Inc. (Chicago, IL), used for chronic pain -- back pain, migraine, fibromyalgia, sciatica, neck/joint/pelvic/hip pain -- via a biopsychosocial, mind-body pain-reprocessing program (pain education, CBT, meditation, expressive writing, somatic tracking). Sold purely direct-to-consumer on a self-pay annual-subscription basis (no Medicare DMHT, commercial-payer, or employer-sponsored channel identified); HSA/FSA-eligible, and clinicians can refer patients to 6 weeks of free access via the "Curable Connect" portal. No FDA clearance identified -- marketed as a general wellness/self-management program rather than a regulated medical device. Its core program is supported by a published randomized controlled trial (Thomson et al 2024, Canadian Journal of Pain; n=198, 6-week intervention vs. wait-list control, improved pain severity and interference; the paper won the journal's 2024 Paper of the Year award).

6-week core program (ongoing self-paced use thereafter)

Curafida (ZTM Bad Kissingen) is a remote-monitoring / digital health platform, developed by ZTM Bad Kissingen GmbH (Zentrum für Telemedizin e.V. / Stiftung Innovative Gesundheitsversorgung), used for chronic heart-failure remote monitoring (vital-sign telemonitoring); platform also used for other indications e.g. Multiple sclerosis ('MS-intakt'). It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since Jan 2022 where a contracted physician bills the national HFTM codes; the sekTOR-HF Innovationsfonds pilot itself (Jun...

CureApp AUD (marketed as HAUDY) is a digital therapeutic (DTx), developed by CureApp, Inc. (developer); Sawai Pharmaceutical (commercial distribution), used for alcohol use disorder / drinking-reduction treatment. It is reimbursed nationally in Japan via an NHI Chuikyo (Central Social Insurance Medical Council) listing. Reimbursed since 1 Sept 2025 -- NHI-listed; 3rd CureApp product to reach reimbursement, commercialised in partnership with Sawai Pharmaceutical as 'HAUDY'.

CureApp HT is a digital therapeutic (DTx), developed by CureApp, Inc., used for hypertension, adjunct to lifestyle-modification therapy. It is reimbursed nationally in Japan via an NHI Chuikyo (Central Social Insurance Medical Council) listing. Reimbursed since 1 Sept 2022 -- NHI reimbursement price: JPY7,010.

CureApp SC is a digital therapeutic (DTx), developed by CureApp, Inc., used for nicotine dependence / smoking cessation, used alongside varenicline. It is reimbursed nationally in Japan via an NHI Chuikyo (Central Social Insurance Medical Council) listing. Reimbursed since 1 Dec 2020 -- NHI reimbursement price: 2,540 points (~JPY25,400) per course of treatment.

Cureety Techcare is a remote-monitoring platform for people undergoing cancer treatment. Patients complete follow-up questionnaires at set intervals, organised by therapeutic class for systemic treatments and by anatomical site for radiotherapy; questions and answers follow the CTCAE standard, so symptom grading rests on objective criteria rather than free text. Responses are triaged automatically and only those crossing a threshold are escalated to the care team. The same product is listed in Belgium under the mHealthBELGIUM cancer-telemonitoring pathway.

Ongoing during anticancer treatment

Cureety Techcare is a remote-monitoring platform for people undergoing cancer treatment. Patients complete follow-up questionnaires at set intervals -- organised by therapeutic class for systemic treatments and by anatomical site for radiotherapy -- whose questions and answers follow the CTCAE standard (Common Terminology Criteria for Adverse Events), so grading rests on objective criteria rather than a free-form scale. Each answer carries a score; the total places the patient in a clinical classification (correct, fragile, to be monitored, critical). Amber and red cases both alert the care team and prompt the patient to contact the hospital, while lower grades return self-management advice for grade 1 and 2 adverse events. A telephone module covers patients who cannot or prefer not to use the app: a team member enters their answers during a call and the same analysis runs, so the whole cohort stays in remote follow-up rather than only its digital-capable part. In Belgium the product sits at level M3 of the mHealthBELGIUM validation pyramid -- the reimbursed tier.

Ongoing during anticancer treatment

CyberHealth is a digital prevention programme, developed by CyberHealth, used for platform of 11 certified 8-week online prevention courses (weight loss, back coaching, yoga, pilates, diabetes prevention, PMR relaxation, smoking cessation, nutrition). Video modules plus downloadable materials and a short weekly questionnaire, on-demand via app or browser. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Certified Sec.20 SGB V online courses meeting the GKV-Spitzenverband's Leitfaden Praevention requirements; most statutory insurers...

8 weeks

Das Lab (DasLab) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, used for colorectal cancer screening. At-home stool test, digital lab report, and (for positive results) a video consultation with a telemedicine physician plus onward referral. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

One-time screening (not an ongoing programme)

Daylight (DaylightRx) is a digital therapeutic (DTx), developed by Big Health, used for generalised anxiety disorder. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 -- Billed by the prescribing clinician: G0552 + G0553/G0554.

DBLG1 System (Diabeloop) is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (Dexcom G6), with the DBLG1 algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

DE-RENA / DE-RENA 2.0 is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Binacon GmbH (Mannheim, Germany), used for psychosomatic Reha-Nachsorge for depressive disorders. (smartphone) app supporting individual daily-structure planning to help patients sustain newly-learned coping behaviours after psychosomatic rehab, with regular contact to an assigned aftercare therapist. It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Not fixed (duration tied to individual DRV aftercare period)

Deep Care (Isa) is a digital prevention programme, developed by Deep Care GmbH, used for workplace ergonomics, posture, stress and indoor air-quality monitoring. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

deprexis is a digital therapeutic (DTx), developed by GAIA AG, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR228.00/90-day Rx (diga.bfarm.de).

deprexis (CH) is a digital therapeutic (DTx), developed by GAIA AG, used for mild-to-moderate depression, recurrent depressive disorders. It is reimbursed nationally in Switzerland via the MiGeL/dGA listing (OKP compulsory insurance). OKP (Obligatorische Krankenpflegeversicherung, compulsory health insurance) covers a Höchstvergütungsbetrag (HVB, max. reimbursement amount) of CHF193.32 out of a CHF271.32 total price; the remaining Selbstbehalt (co-payment) is often covered by supplementary insurance (Zusatzversicherung); requires prescription by a psychiatry/psychotherapy specialist or a...

dermanostic is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by dermanostic GmbH, used for skin conditions incl. acne, eczema, psoriasis, suspicious moles. Photo + questionnaire teledermatology, reviewed by a board-certified dermatologist. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

detoxi Health App is a digital prevention programme, developed by detoxi Health GmbH, used for digital stress management. App-blocking, focus sessions and 300+ "life hacks" to reduce screen time and digital stress. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). SHI-reimbursed up to 100% of EUR99.99 course fee after completing 40 missions over 9 weeks and submitting a participation certificate; ZPP-certified under Sec.20 Abs.1 SGB V, course ID KU-ST-4JDL2F.

9 weeks

Dexcom Clarity (Dexcom G6/G7, GB) is a connected medical device (with companion software), developed by Dexcom Inc., used for type 1 diabetes (all ages); insulin-treated type 2 diabetes meeting local eligibility criteria. It is reimbursed nationally in the United Kingdom via the NICE NG17 pathway. Reimbursed (NHS-funded sensor; companion app free) -- Same NICE NG17 national pathway as FreeStyle LibreLink above; Dexcom G6/G7 sensors prescribed via NHS diabetes services, Dexcom Clarity is the free companion analytics app (also has a clinician-facing web platform).

Dexcom G6 / G7 is a connected medical device (with companion software), developed by Dexcom Inc., used for insulin-treated diabetes. It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed (individual case approval by Krankenkasse).

Diabeloop DBLG1 is a connected medical device (with companion software), developed by Diabeloop SA, used for type 1 diabetes (inadequate control on insulin pump). It is reimbursed nationally in France via the LPPR pathway. LPPR codes 1177410 (terminal) & 1102872 (daily algorithm licence); limited to adults with >6 months intensive insulin pump therapy and insufficient glycaemic control.

Diabeo is a digital therapeutic, developed by Voluntis, used for insulin-dose titration support for insulin-treated diabetes patients -- mobile app calculates bolus/basal dose recommendations from blood-glucose and carbohydrate data, with an optional clinician web portal for telemonitoring. Reimbursed on France's LPP since a September 2016 HAS opinion -- reported as the first digital health app reimbursed by French statutory health insurance (Assurance Maladie).

EasyBreath is a digital therapeutic (DTx), developed by Share&Service (쉐어앤서비스), used for COPD, asthma, lung-cancer-related. Respiratory rehabilitation. It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

eatappie is a digital therapeutic (DTx), developed by Mind Generation GmbH (Heidelberg, founded Sept 2023 -- EXIST-Gründerstipendium spin-off; founders Dr. med. Larissa Niemeyer and Dr. med. Szarah Sanchez Roman, ex-Zentralinstitut für Seelische Gesundheit), used for anorexia and bulimia nervosa in adolescents (12-18); digital CBT-based companion, bridges waiting times and supports post-inpatient follow-up. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (ongoing access while TK-insured)

eCovery - Therapie bei Schmerzen im unteren Rücken is a digital therapeutic (DTx), developed by eCovery GmbH, used for lower back pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR574.00/90-day Rx (diga-verzeichnis.de).

eCovery (AOK PLUS Satzungsleistung -- non-DiGA indications) is a digital therapeutic (DTx), developed by eCovery GmbH (same manufacturer as the lower-back DiGA), used for upper back pain, hip pain, knee pain (incl. Osteoarthritis/cartilage wear, meniscus issues) and pre-/post-operative care for total hip or knee replacement (TEP); TEP patients pay a EUR99 co-payment out of a EUR399 total, all other indications fully covered up to the EUR300 cap. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 months (annual benefit cap)

eduMovo is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, used for multimodal digital rehabilitation aftercare. Interactive learning units, individual training plans, task management, chat/video contact with the aftercare team. It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Not fixed (duration tied to individual DRV aftercare period)

edupression.com is a digital therapeutic (DTx), developed by edupression GmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR224.80/90-day Rx (diga.bfarm.de).

EGYM Wellpass (formerly qualitrain) is a digital prevention programme, developed by EGYM Wellpass GmbH (part of EGYM GmbH), used for general fitness and wellness access. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

elevida is a digital therapeutic (DTx), developed by GAIA AG, used for multiple sclerosis (fatigue/mental health support). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR243.00/90-day Rx (diga.bfarm.de).

elona explore - für die mentale Gesundheit is a digital therapeutic (DTx), developed by Elona Health GmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR535.49/90-day Rx (diga-verzeichnis.de).

elona therapy Depression is a digital therapeutic (DTx), developed by Elona Health GmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR229.50/90-day Rx (diga.bfarm.de).

EndeavorOTC is an FDA-cleared, over-the-counter digital therapeutic, developed by Akili Interactive Labs, Inc. (Boston, MA), used for ADHD-related inattention in adults. It uses the same game-based mechanism as Akili's prescription product EndeavorRx (tracked separately for children ages 8-12), cleared in Jun 2024 as a distinct, adult-facing, non-prescription SKU. It is sold direct-to-consumer through app stores on a self-pay basis, independent of Medicare DMHT billing or commercial-payer contracts.

4 weeks minimum (25 min/day, 5 days/week)

ENDEAVORRIDE is a digital therapeutic (DTx), developed by Shionogi & Co., Ltd. (Japan rights; underlying technology from Akili Interactive, USA), used for paediatric ADHD, ages 6-17, when environmental/psychosocial interventions are insufficient. It is reimbursed nationally in Japan via an NHI Chuikyo (Central Social Insurance Medical Council) listing. Approval 13 Feb 2025; reimbursement effective 5 Jun 2026 -- NHI reimbursement: material fee 1,450 points for the app + guidance-management fee (B005-14: 90 points) + induction-phase add-on (50 points); limited to 2 prescriptions per patient.

EndeavorRx is a digital therapeutic (DTx), developed by Akili Interactive Labs, Inc. (Boston, MA; a wholly-owned subsidiary of Virtual Therapeutics since a July 2024 tender offer), used for ADHD -- inattention in children and teens (ages 8-17). Delivered as a video-game-based intervention played roughly 25 minutes a day, 5 days a week, for a minimum of 4 weeks, it received FDA De Novo clearance in 2020 as the first prescription treatment delivered through a video game (label expanded from ages 8-12 to 8-17 in Dec 2023). It is reimbursed nationally in the US via Medicare's DMHT G-codes (G0552-G0554) since 1 Jan 2026, after CMS's CY2026 Physician Fee Schedule Final Rule extended DMHT payment eligibility to ADHD digital-therapy devices under 21 CFR 882.5803 -- the device classification created for EndeavorRx's own clearance. It remains selectively covered by some commercial payers and state Medicaid plans via outcome-based contracts (e.g. Highmark BCBS, Molina Medicaid Ohio) alongside the new Medicare pathway; other payers still classify it as investigational. A self-pay, non-prescription OTC version (EndeavorOTC, for adults) is also available independent of insurance.

4 weeks minimum (25 min/day, 5 days/week)

Endo-App is a digital therapeutic (DTx), developed by Endo Health GmbH, used for endometriosis. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.80/90-day Rx (diga.bfarm.de).

endogApp is a hospital patient-information and care-pathway companion app, developed by endogap Klinik für Gelenkersatz (Klinikum Garmisch-Partenkirchen GmbH), used for perioperative patient information and individual treatment timeline for hip and knee joint replacement surgery at endogap Klinik für Gelenkersatz (Klinikum Garmisch-Partenkirchen). It is provided free in Germany by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any insurer, employer or the patient.

enna care combines a home emergency call system with a voice assistant for older people living alone, plus an app for relatives. Beyond the emergency button it offers reminders, orientation and spoken everyday assistance, which the manufacturer gives as the reason a co-payment remains rather than the system being fully covered: "Weil enna mehr kann als ein reines Notrufgerät, bleibt ein Eigenanteil von 9,90 EUR im Monat". Funding runs through the long-term care insurance: enna joined the GKV framework contract for home emergency call services and announced the first confirmed Pflegekasse approvals on 9 September 2026. A care level of Pflegegrad 1 or above and living largely alone at home are the stated conditions -- about 80% of its users according to the company -- and enna files the application digitally during ordering. Pricing: EUR 9.90/month with the subsidy on a 12-month term, EUR 39.90/month as a self-payer, EUR 4.90 shipping, 30-day free trial. Notable as a reimbursement pattern: the provider is licensed through a framework contract, so a product listing in the Hilfsmittelverzeichnis is not required -- and enna appears in neither of the two groups that would otherwise apply (52.40.01 home emergency call systems, 52.40.05 modular assistance systems).

Subscription, 12-month term on the subsidised tariff; a monthly cancellable tariff is also offered

EvoCare is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by EvoCare Telemedizin ECT eG (Nuremberg/Erlangen area, Germany; own site states founded 2018, though the underlying telemedicine methodology traces to DRV-funded research at Fachklinik Herzogenaurach from ~1999-2004), used for multimodal digital rehabilitation aftercare across orthopaedics (chronic back pain, joint-replacement aftercare), cardiology (coronary heart disease secondary prevention), neurology (aphasia, stroke, cognitive/attention training) and general...

Not fixed (duration tied to individual DRV aftercare period)

FEMNA Care is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Femna Health M.E. GmbH (Berlin, founded 2016 by Maxie Matthiessen and Emily Casey), used for endometriosis, PCOS, PMS/PMDD, menstrual pain/cycle complaints, menopause. Includes 3 individual coaching sessions with medical professionals per programme. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 months (VIACTIV); duration at other partner funds not centrally published

FibriCheck is a remote-monitoring / digital health platform, developed by FibriCheck NV, used for atrial fibrillation / arrhythmia detection (smartphone PPG). It is reimbursed nationally in Belgium.

Fimo Health is a digital therapeutic (DTx), developed by Fimo Health GmbH (Bonn, founded 30 Dec 2019), used for long Covid, ME/CFS, cancer, multiple sclerosis, fibromyalgia, rheumatoid arthritis (chronic-disease companion, not single-indication). It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

6 months (mhplus Krankenkasse); duration at other partner funds not centrally published

FIT UND GESUND COACH is a digital prevention programme, developed by FIT UND GESUND COACH, used for starke Beine (Kniekrafttraining), Vom Walken zum Laufen and Rueckenfit. Movement-focused online prevention courses. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). ZPP-zertifiziert nach Sec.20 SGB V; EUR119, bis zu 100% Erstattung durch die gesetzliche Krankenkasse.

Flowzone is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Flow Technologies (Oslo, Norway -- not a German company, but operates as a DRV-recognised aftercare provider in Germany), used for digital rehabilitation aftercare with 600+ exercises/seminars for orthopaedic and cardiac indications. It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Not fixed (duration tied to individual DRV aftercare period)

ForPatientApp (B. Braun) is a remote-monitoring / digital health platform, developed by B. Braun Melsungen AG, used for perioperative guidance for hip and knee replacement, spine surgery, hernia surgery and colorectal surgery. Pre-op preparation, post-op recovery information, an assignable exercise programme (ForPatientApp Move), and PROM/PREM (patient-reported outcome/experience measure) data collection. It is provided free in Germany by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any insurer, employer or the patient.

Freespira is an FDA-cleared digital therapeutic, developed by Freespira, Inc. (Menlo Park, CA), used for panic attacks (panic disorder) and PTSD. It pairs a home-use breathing-sensor device with a 28-day program of twice-daily sessions to normalize respiration patterns linked to panic and hyperarousal symptoms. Cleared by the FDA since 2018 for adults, with a 2025 expansion to adolescents (13-17), it is reimbursed by several named commercial health plans and is eligible for Medicare billing under the DMHT G-codes (G0552-G0554), the same reimbursement family used by Akili, Big Health and Otsuka's prescription digital therapeutics.

28-day program (2 sessions/day)

FreeStyle Libre (2 / 3) is a connected medical device (with companion software), developed by Abbott Diabetes Care, used for insulin-treated diabetes (type 1 and insulin-treated type 2). It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since 2016 (Libre); Libre 2 added 2019.

FreeStyle Libre Flash Glucose Monitoring System (BE) is a connected medical device (with companion software), developed by Abbott SA/NV, used for interstitial glucose measurement for people (4+) with diabetes mellitus, including pregnant women; replaces blood-glucose testing for insulin dosing. It is reimbursed nationally in Belgium.

FreeStyle LibreLink (GB) is a connected medical device (with companion software), developed by Abbott Diabetes Care, used for type 1 diabetes (all ages); insulin-treated type 2 diabetes meeting local eligibility criteria. It is reimbursed nationally in the United Kingdom via the NICE NG17 pathway. Reimbursed (NHS-funded sensor; companion app free) -- NICE NG17 recommends offering rtCGM or isCGM to ALL adults/children with type 1 diabetes based on individual preference and device functionality; insulin-treated type 2 diabetes covered under narrower local-ICB criteria (typically multiple...

Frieda Menova is a digital therapeutic (DTx), developed by Frieda Health GmbH, used for menopause and climacteric symptoms (vasomotor symptoms, sleep disturbance, psychological distress). A 12-week cognitive behavioral therapy (CBT) programme covering psychoeducation, cognitive restructuring, breathing/relaxation techniques, sleep hygiene and symptom tracking, developed with an interdisciplinary team spanning gynaecology, psychology and technology under the medical direction of Prof. Dr. med. Petra Stute (chief physician for gynaecological endocrinology; president of the European Menopause and Andropause Society). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway, provisionally listed as of 7 Sep 2026.

12 weeks

Gesundheitskurs.de (Plattform) is a digital prevention programme, developed by Gesundheitskurs.de, used for platform hosting multiple ZPP-certified online prevention courses across movement, nutrition and stress/resilience, recognised by German statutory insurers. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Platform for ZPP-certified prevention courses; all listed courses are certified under §20 SGB V; reimbursement of up to 100% depending on the statutory health insurer.

Glooko XT (Candiss) is a remote-monitoring platform for diabetes management, developed by Glooko SAS (a French subsidiary of Glooko, Inc.), used for gestational diabetes monitoring in non-insulin-treated patients. It is reimbursed nationally in France via the LATM telemonitoring pathway. Listed on France's LATM list, Journal Officiel 26 Dec 2024; base tariff approx. EUR28/month per patient; indication limited to non-insulin-treated gestational diabetes (positive OGTT weeks 24-28, or fasting glucose >=0.92 g/L in the first trimester with a risk factor).

glucura Diabetestherapie is a digital therapeutic (DTx), developed by Perfood GmbH, used for type 2 diabetes. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR499.80/90-day Rx (diga.bfarm.de).

GoJoe is a digital prevention programme, developed by GoJoe Ltd., used for general social/team fitness challenges and physical, mental and social wellbeing. Not indication-specific. It is offered in the United Kingdom as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Grokker is a digital prevention programme, developed by Grokker, Inc., used for general physical, emotional and financial wellbeing via video content. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Gymlib is a digital prevention programme, developed by Gymlib SAS, used for general fitness and wellness facility access. Not indication-specific. It is offered in France as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Gymondo Praeventionskurse is a digital prevention programme, developed by Gymondo GmbH, used for rueckenfit, Laufen and Funktionelle Ganzkoerperkraeftigung. Movement-based online prevention courses guided by physiotherapists/Reha-Trainer. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Offiziell nach Sec.20 Abs.1 SGB V durch die ZPP zertifiziert; bis zu 100% Kostenerstattung durch die gesetzliche Krankenkasse; EUR99 je Kurs.

10 weeks

Hainan Class II DTx #4 -- Exercise/Cardiopulmonary Rehab Training Software (运动康复训练软件) is a digital therapeutic (DTx), used for cardiopulmonary rehabilitation. Structured exercise-training programme to aid clinicians guiding patients through cardiopulmonary function rehab. It is billable in China (Hainan province) under a provincial fee-schedule, not yet nationwide health insurance.

Hainan Class II DTx #5 -- Pulmonary Function Rehab Training Software (肺功能康复训练软件) is a digital therapeutic (DTx), used for pulmonary (lung) function rehabilitation. Structured training programme to aid clinicians guiding patients through pulmonary rehab. It is billable in China (Hainan province) under a provincial fee-schedule, not yet nationwide health insurance.

Hainan Class II DTx #6 -- Cardiopulmonary Walking-Test Data Analysis Software (心肺步行试验数据分析软件) is a digital therapeutic (DTx), used for exercise cardiopulmonary function assessment. Analyses walking-test data to assist medical staff (no automated diagnosis). It is billable in China (Hainan province) under a provincial fee-schedule, not yet nationwide health insurance.

Hainan Class II DTx #7 -- Cognitive Impairment Assessment & Training Software (认知功能障碍评估与训练软件) is a digital therapeutic (DTx), used for mild cognitive impairment. Adjunct assessment and training aid. It is billable in China (Hainan province) under a provincial fee-schedule, not yet nationwide health insurance.

Hansefit is a digital prevention programme, developed by Hansefit GmbH (part of Epassi Group), used for general fitness and wellness access, plus individually rewarded health activities. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Headspace for Work / Headspace Care (incl. Ginger) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Headspace Health, Inc. (Headspace + Ginger), used for mindfulness, stress, anxiety, depression and general mental-health support. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Healabs is a remote-monitoring / digital health platform, developed by Healabs, used for cardiac & renal remote monitoring. It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

Health Hero (Long-COVID-Service) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by HealthHero Germany GmbH (formerly Fernarzt; part of the pan-European HealthHero group since 2020), used for long-COVID / Post-COVID syndrome. Digital symptom-checker followed by a specialist video consultation with Long-COVID-trained doctors, plus an optional independent-rehabilitation coaching track. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (symptom-check + consultation, plus optional coaching track)

Healthclapp is a digital prevention programme, developed by Healthclapp (Schuljahr & Putz), used for general workplace physical activity motivation. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Healthentia is a remote-monitoring / digital health platform, developed by Innovation Sprint, used for digital biomarkers / remote monitoring (multi-pathology, incl. Heart failure). It is reimbursed nationally in Belgium.

hedy Telemonitoring is a connected medical device (with companion software), developed by Health Care Systems GmbH (HCSG), used for chronic heart failure remote monitoring (external measurement devices). It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since Jan 2022.

HelloBetter Chronische Schmerzen is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for chronic pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.00/90-day Rx (diga.bfarm.de).

HelloBetter Diabetes is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for type 1 and type 2 diabetes (psych. comorbidity). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR222.99/90-day Rx (diga.bfarm.de).

HelloBetter Panik is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for panic disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR230.00/90-day Rx (diga.bfarm.de).

HelloBetter Schlafen is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for insomnia. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR241.25/90-day Rx (diga.bfarm.de).

HelloBetter Stress und Burnout is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for stress & burnout. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.00/90-day Rx (diga.bfarm.de).

HelloBetter Vaginismus Plus is a digital therapeutic (DTx), developed by HelloBetter GmbH (GET.ON Institut), used for vaginismus. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.00/90-day Rx (diga.bfarm.de).

HELP (HELP Schmerztherapie) is a digital therapeutic (DTx), developed by HELP Mee Schmerztherapie GmbH (founder/CEO Dr. med. Antje Kallweit, specialist in anaesthesiology / special pain therapy), used for chronic 'nociplastic' pain (i.e. pain sustained by nervous-system processing rather than ongoing tissue damage). Fibromyalgia, chronic back/neck pain, persistent pelvic pain, or pain that persists after an injury/surgery has otherwise healed; 90-day, 24-module programme covering pain-neuroscience education, neuroplasticity-based exercises, and behavioural-medicine techniques; earmarked...

90 days (24-module programme); 5-day trial option also available

Herodikos (Herodikos App / Herakles) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Herodikos GmbH (Varel, Niedersachsen, 2019), used for back pain, neck pain, knee pain. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Ongoing (no fixed programme length found)

Hinge Health (core MSK programme) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for musculoskeletal pain. Back, joint, knee, shoulder and general chronic pain. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Hinge Health Global -- Germany is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for musculoskeletal pain (same core programme as the US employer offering). It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Hinge Health Global -- United Kingdom is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for musculoskeletal pain (same core programme as the US employer offering). It is offered in the United Kingdom as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Hinge Health Migraine Care Program is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for migraine. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Hinge Health Women's Pelvic Health is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for pelvic-floor disorders. Prolapse, diastasis recti (abdominal separation), bladder/bowel problems, chronic pelvic pain; across pregnancy, postpartum and menopause. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

HingeSelect is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Hinge Health, Inc., used for musculoskeletal conditions requiring in-person/specialist follow-up (surgical candidates, high-risk members). It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

hiToco(R): ADHS Elterntraining is a digital therapeutic (DTx), developed by Medigital GmbH (MEDICE Health Family), used for ADHD (parent training, children). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR479.20/90-day Rx (diga.bfarm.de).

Humanoo is a digital prevention programme, developed by Humanoo GmbH (trading as eTherapists GmbH), used for general workplace fitness, physiotherapy, yoga, meditation, nutrition and sleep. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Hyperhero (brainjo) is a digital therapeutic (DTx), developed by brainjo (Regensburg, Germany, founded 2022), used for ADHD (children, ages 8-13). A VR-based therapy delivered across 24 sessions in 5 modules over roughly 3 months (~40 minutes per session), developed in partnership with MEDICE and backed by EUR2M HTGF seed funding (Apr 2026). It is available in Germany on a self-pay basis while the company pursues DiGA listing, targeted for 2028.

3 months (24 sessions across 5 modules, ~40 min/session)

ieso Digital Health (Mindler) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by ieso Digital Health (trading as Mindler), used for depression, anxiety and related common mental health conditions. It is reimbursed in the United Kingdom through regional or insurer-specific contracts rather than a nationwide scheme.

Implicity is a remote-monitoring platform from Implicity SAS (Paris, founded 2016 by Dr Arnaud Rosier) for patients with cardiac implantable electronic devices. It aggregates data from implanted defibrillators, pacemakers and implantable cardiac monitors across manufacturers into a single clinician-facing view, with alert triage intended to reduce the review burden on cardiology teams. In France it moved in 2026 from the PECAN early-access scheme to the standard télésurveillance list under Article L. 162-52 of the Code de la sécurité sociale, across three indications: implantable defibrillators, pacemakers, and implantable cardiac monitors.

IncentFit is a digital prevention programme, developed by IncentFit, Inc., used for general fitness, wellness benefits and reimbursements. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

INKA is a digital therapeutic (DTx), developed by nextec medical GmbH, used for urinary incontinence. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR670.49/90-day Rx (diga.bfarm.de).

InTandem is an FDA-cleared, home-use digital therapeutic device, developed by MedRhythms, Inc. (Portland, ME), used for gait and mobility impairment after chronic stroke. It combines wearable movement sensors with auditory rhythmic cueing to guide walking rehabilitation. Following a 2020 FDA Breakthrough Device designation and 2023 Class II clearance, CMS finalized a dedicated Medicare Durable Medical Equipment billing code (HCPCS E3200) in Jan 2025, giving an estimated 15 million Medicare beneficiaries and roughly 800,000 chronic-stroke patients a reimbursement pathway to access it.

Ongoing home-use therapy

Invirto - Die Therapie gegen Angst is a digital therapeutic (DTx), developed by Sympatient GmbH, used for anxiety disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR220.00/90-day Rx (diga.bfarm.de).

isi PMS App is a digital therapeutic (DTx), developed by Endo Health GmbH, used for premenstrual syndrome (PMS). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR598.95/90-day Rx (diga.bfarm.de).

JawBuddy is a jaw-exercise and tracking app, developed by JawBuddy GmbH (Leipzig, Germany) with dentists and physiotherapists, used for jaw pain, bruxism (teeth grinding) and temporomandibular joint (TMJ/CMD) tension. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified): a standalone "Progressive Muskelentspannung" course (Jacobson PMR technique), 8 weeks at 8x45 minutes, delivered entirely within the JawBuddy app (ZPP course ID KU-ST-73WY6K). SHI-reimbursed up to EUR59.99 course fee after completion and submission of a participation certificate; manufacturer states completion also includes 6 months of full app access.

JOE (Digital Therapy JOE) is a connected medical device (with companion software), developed by Ludocare SAS, used for persistent paediatric asthma (ages 7-11). It is reimbursed nationally in France via the LPPR pathway. Pending: CEPS price negotiation, then publication in Journal Officiel before reimbursement is active.

kaarloApp is a digital therapeutic, developed by kaarlo health GmbH (Essen, Germany), used for somatoform and functional bodily disorders (ICD-10 F45.-) -- symptoms such as fatigue, dizziness, headache, back pain and exhaustion that are not sufficiently explained by organic causes. It combines a modular digital self-therapy programme with on-demand human support by video call (kaarloDoc), and is certified as a medical device. It is not a DiGA: it does not appear in BfArM's DiGA-Verzeichnis, listed or struck, as of Oct 2026. Access today is free of charge via a study; a selective-contract route with statutory insurers is in preparation following the GWQ ServicePlus / HAEVG innovation process of 2026, but no contract or start date has been published.

Kaia COPD: Meine aktive COPD Therapie is a digital therapeutic (DTx), developed by Kaia Health Software GmbH (acquired by Sword Health, Jan 2026), used for COPD (chronic obstructive pulmonary disease). Breathing/relaxation/movement exercise programme with an AI-based camera exercise coach. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

90 days (per activation code)

Kaia Rückenschmerzen is a digital therapeutic (DTx), developed by Kaia Health Software GmbH, used for back pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR221.49/90-day Rx (diga-verzeichnis.de).

Kalmeda is a digital therapeutic (DTx), developed by Pohl-Boskamp Digital Health GmbH, used for chronic tinnitus. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR189.00/90-day Rx (diga.bfarm.de).

Kira-App is a digital therapeutic (DTx), developed by Endo Health GmbH (Chemnitz, Germany, founded 2020 as Endo Health UG by Nadine Rohloff), used for people coping with an unfulfilled desire to have children. A multimodal self-management companion (symptom/cycle/treatment diary, learning modules from reproductive medicine, psychology and nutrition, interactive exercises) addressing both the physical and emotional dimensions of fertility struggles. It is a CE-marked Class I medical device, free to download, but not yet listed in BfArM's DiGA directory. Any cost to unlock full content was not confirmed from public sources.

Kiso Mind is a digital therapeutic, developed by Kiso Health GmbH (Berlin), a spin-off of Charite Universitaetsmedizin Berlin, used for schizophrenia and psychotic disorders. It delivers exercises from cognitive behavioural therapy alongside symptom self-monitoring, psychoeducation, reminders and a crisis plan, and is built with psychologists, psychotherapists and people with lived experience of psychosis; a companion app, Kiso Care, addresses relatives. It is a CE-marked Class I medical device under MDR. It is not reimbursed: the basic version is free, a Plus version is paid, and the company describes statutory cost coverage as in preparation. A randomised pilot trial runs at the Charite (NCT07395206).

klariva is a digital therapeutic (DTx), developed by GAIA AG (Hamburg, Germany, founded 2002 as GAIA Gesundheitsmanagement GmbH), used for psoriasis. A web-based, psychologically-oriented programme addressing the mental and emotional burden of psoriasis (self-esteem, mindfulness, sleep, weight, habit-building) alongside regular medical treatment. It is not yet self-pay or DiGA-reimbursed -- the public site only offers a login for existing study participants, with no purchase path found; GAIA has described Germany as the planned first launch market ahead of international expansion.

Klenico is a web-based diagnostic support system for mental health. Patients complete a structured self-report module; the system maps the responses onto disorder domains and presents the clinician with a structured diagnostic picture before the first consultation, which the company positions as a way to reduce lengthy test batteries. It is a CE-marked medical device and is unusually well validated for this category: three peer-reviewed validation studies, including a comparison against the SCID diagnostic gold standard and a large psychotherapeutic inpatient sample. In Switzerland it is not on the MiGeL and not covered by mandatory basic insurance -- it reaches patients through agreements with individual insurers (Sanitas and KPT are named), and is sold directly to therapists and clinics.

Per assessment, no fixed programme length

Koa Health iCT-PTSD is a digital therapeutic (DTx), developed by Koa Health, used for post-traumatic stress disorder (PTSD). It is reimbursed nationally in the United Kingdom via the NHS Talking Therapies DET pathway. NHS England DET-compliant, nationally usable within NHS Talking Therapies -- Commissioned locally by individual NHS Talking Therapies services, drawn from NICE's nationally-vetted DET list.

Koa Health iCT-SAD is a digital therapeutic (DTx), developed by Koa Health, used for social anxiety disorder (SAD). It is reimbursed nationally in the United Kingdom via the NHS Talking Therapies DET pathway. NHS England DET-compliant, nationally usable within NHS Talking Therapies -- Commissioned locally by individual NHS Talking Therapies services, drawn from NICE's nationally-vetted DET list.

Kranus Edera is a digital therapeutic (DTx), developed by Kranus Health GmbH, used for erectile dysfunction. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.00/90-day Rx (diga.bfarm.de).

Kranus Lutera is a digital therapeutic (DTx), developed by Kranus Health GmbH, used for prostate enlargement / urinary urgency. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR240.50/90-day Rx (diga.bfarm.de).

Kranus Mictera is a digital therapeutic (DTx), developed by Kranus Health GmbH, used for urinary incontinence. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR681.30/90-day Rx (diga.bfarm.de).

levidex is a digital therapeutic (DTx), developed by GAIA AG, used for multiple sclerosis (mental health support). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR247.81/90-day Rx (diga.bfarm.de).

Lifton D (リフトンD) is a digital therapeutic (program medical device / SaMD), developed by DT-Axis Co., Ltd., used for depression -- specifically relief of moderate-to-severe depressive symptoms that persist despite ongoing pharmacotherapy. It delivers a 20-week cognitive-behavioural-therapy programme alongside antidepressant treatment, and is built on research from Kyoto University. It received manufacturing and marketing approval on 25 Sep 2025 as Japan's first program medical device for depression. From 1 Jun 2026 it is designated 評価療養 (evaluation therapy) through 31 May 2030 -- a mixed-billing framework rather than reimbursement: the patient pays for the app on top of the normal insurance co-payment while real-world data is collected toward a possible future NHI listing.

20 weeks

Limeade is a digital prevention programme, developed by Limeade, Inc., used for general employee wellbeing and organisational-listening/survey tools. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Lina-App is a digital therapeutic (DTx), developed by Endo Health GmbH (Chemnitz, Germany, founded 2020 as Endo Health UG by Nadine Rohloff), used for lipedema (Lipödem). A multimodal self-management companion combining a symptom/pain diary with learning modules and exercises drawn from lymphology, phlebology, physiotherapy, pain medicine, nutrition and psychology. It is a CE-marked Class I medical device, free to download, but not yet listed in BfArM's DiGA directory -- a direct search of the official registry returns no lipedema DiGA at all as of this research. Any cost to unlock full content was not confirmed from public sources.

Lindera Mobilitätsanalyse (Sturz-App) is a digital prevention programme, developed by Lindera GmbH, used for fall-risk assessment / mobility analysis in older adults. AI analyses gait from a short smartphone-camera video to calculate individual fall risk, used mainly in nursing/care settings by staff, with results reviewed by clinicians/therapists for fall-prevention planning; Charite-affiliated study cites up to 15-20% fall-risk reduction. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (ongoing access in care setting)

LipoAlly is a digital therapeutic (DTx), used for 12-month lipedema (Lipödem) companion programme. Video modules with medicine/therapy/psychology experts, monthly live courses, movement units, progress documentation. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 months

lipodia is a digital therapeutic (DTx), developed by GAIA AG (Hamburg, Germany, founded 2002 as GAIA Gesundheitsmanagement GmbH), intended for adults with hypercholesterolemia as part of cardiovascular risk management. Daiichi Sankyo Europe holds exclusive commercialisation rights, with Germany as the initial launch market. It is not yet accessible to patients in any form -- a pivotal Phase III randomized controlled trial is currently enrolling, and GAIA plans to submit lipodia for DiGA (Sec.139e SGB V) reimbursement once the trial data are available.

Luma Life is a voice-based AI companion for people living with dementia and their family carers at home. A friendly avatar provides reminders, spoken conversation and cognitive games, with the stated aim of more structure and independence in daily life and relief for carers. It is paid for entirely out of pocket in Germany: a permanently free tier (10 min conversation/day, 3 calendar entries, up to 2 carers), Solo at EUR 30/month or EUR 300/year, Familie at EUR 50/month or EUR 500/year (30-day trial, no card required), and an Unbegrenzt tier at EUR 200/month. It is not a medical device and not a detection or screening tool.

Subscription, no fixed programme length

Lumi Nova is a digital therapeutic (DTx), developed by BFB Labs, used for mild-to-moderate anxiety, ages 7-12. It is available in the United Kingdom through a regional or time-limited pilot commissioning arrangement, not (yet) an established national or ongoing regional/selective contract.

Luminopia is an FDA-cleared digital therapeutic, developed by Luminopia, Inc. (Boston, MA), used to treat amblyopia ("lazy eye") in children. Delivered through a VR headset streaming modified television and video content that trains the amblyopic eye during normal at-home viewing, it received FDA De Novo clearance in Oct 2021 for ages 4-7, expanded to ages 8-12 in Apr 2025. It is actively covered by named commercial payers including Anthem Blue Cross Blue Shield and CareFirst BlueCross BlueShield.

Prescribed course, typically several months

Luscii is a remote patient monitoring platform, developed by Luscii Healthtech B.V. (Amsterdam, Netherlands; an OMRON Healthcare company since its April 2024 acquisition), used for chronic-disease monitoring including heart failure, COPD and hypertension. Founded in 2013 by Ronald Scheffer, Joris Janssen and Daan Dohmen, it combines a patient-facing app with connected monitoring devices and clinician dashboards. The Netherlands has no DiGA-style dedicated digital-therapeutics reimbursement code; instead, Luscii is billed under the general Zvw basic health insurance rules whenever the clinical activity it supports is already covered. Despite the lack of a dedicated pathway, adoption is substantial: reimbursed by an estimated 94% of Dutch insurers and used across the majority of Dutch hospitals.

Ongoing chronic-care management

MamaLift Plus is a digital therapeutic (DTx), developed by Curio Digital Therapeutics, used for postpartum / maternal mental health. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 -- Billed by the prescribing clinician: G0552 + G0553/G0554.

MANN is(s)t smart is a digital prevention programme, developed by Mann-isst-smart / ESG, used for 10-week digital nutrition course for men, covering diet basics, heart health, metabolism and everyday-compatible eating habits. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifiziertes Praeventionsangebot nach Sec.20 SGB V; 80-100% Erstattung durch die gesetzliche Krankenkasse; EUR89.

10 weeks

Mawendo is a digital therapeutic (DTx), developed by Mawendo GmbH, used for patellar conditions / knee pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (one-off licence); manufacturer price EUR119.00 one-off licence (diga.bfarm.de).

Medcle (formerly Med CBT-i) is a digital therapeutic (DTx), developed by SUSMED, Inc. (developer); Shionogi (commercialisation partner), used for insomnia disorder. 9-week CBT-I (cognitive behavioural therapy for insomnia) programme. It is reimbursed nationally in Japan via an NHI Chuikyo (Central Social Insurance Medical Council) listing. Approved for reimbursement 13 May 2026, effective 1 Jun 2026 -- NHI reimbursement price JPY24,100, plus guidance-management fee (B005-14: 90 points) and induction-phase add-on (50 points).

medicalmotion is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by medicalmotion GmbH (Munich, 2017, founders Sven & Tobias Klimpel), used for back and knee pain. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Ongoing (no fixed programme length found)

Medtronic CareLink Network is a connected medical device (with companion software), developed by Medtronic plc, used for pacemaker / ICD / CRT follow-up. It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since 1 April 2016.

Medtronic CareLink Network is the remote-monitoring platform through which recordings from the manufacturer’s implanted cardiac devices reach the treating cardiology team between in-person checks. France reimburses the implantable-cardiac-monitor follow-up activity through a product-specific code per platform, all at an identical rate; the clinical service is the same across vendors and the French tariff reflects that.

Ongoing

Medtrum TouchCare System is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (the integrated Medtrum rtCGM), with the TouchCare algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

Meine Tinnitus App is a digital therapeutic (DTx), developed by BAYOOCARE GmbH and operated by InfectoPharm Digital Health GmbH (Hamburg), used for tinnitus counselling. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (one-off licence); manufacturer price EUR260.00 one-off licence (diga.bfarm.de).

MeineSana (Sana Kliniken) is a hospital patient-information and care-pathway companion app, developed by Sana Kliniken AG, used for perioperative and general-treatment patient information across the Sana Kliniken hospital network. Live variants include hip/knee surgery preparation (Sana Kliniken Sommerfeld), obesity-centre patients (Karl-Olga Hospital Stuttgart), and general hospital-stay guidance (Sana Klinikum Munich, Rummelsberg, Baumann Klinik). It is provided free in Germany by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any...

memodio is a digital therapeutic (DTx), developed by memodio GmbH, used for Alzheimer's dementia, vascular dementia, and mild cognitive impairment (MCI). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR595.00/90-day Rx (diga.bfarm.de).

MENO! is a digital therapeutic (DTx), developed by Sidekick Health ehf (Reykjavik, Iceland; operated in Germany as Sidekick Health Germany GmbH -- the same corporate family behind PINK! Coach and zanadio), used for menopause symptoms. A CE-marked, CBT-based 12-week programme covering symptom tracking, coping strategies and lifestyle guidance. It is currently free to use for patients while the company pursues DiGA listing; the company reports that a German randomized controlled trial (ages 40-65, 12 weeks, vs. standard care) was completed successfully; this has not been published, so the claim could not be independently verified.

12-week programme

mentalis is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by mentalis GmbH (Nuremberg, founded 2018; founders Alexander Ploner, Leonhard Glomann, Dr. Christian A. Lukas, Hans-Jürgen Stein), used for depression (programme 'Phoenix'), eating disorders ('MyJourney'), borderline personality disorder ('InBalance'), emotional-competence training ('TEK'). Algorithm-based therapy app + tele-coaching, set up on the patient's phone before hospital discharge, 26 weeks active + 6 months read-only. It is reimbursed in Germany through...

26 weeks active access + 6 months read-only follow-up

MHComm is a remote-monitoring / digital health platform, developed by MHComm, used for cardiac & renal remote monitoring platform (multi-pathology). It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

Midi Health is a virtual clinic for menopause and perimenopause: video visits with women's health clinicians, prescriptions and a care plan. Reimbursement attaches to the clinician visit, not to a listed product. Midi states it is in-network with most major plans nationwide and specifically with most PPO plans, while deductibles, coinsurance and copays vary by plan; HSA and FSA funds can be used. Two exclusions are stated plainly by the company: Medicare is out of network (beneficiaries are welcome as self-pay but cannot submit claims for visits, medications or associated services), and Medicaid/Medi-Cal patients are not accepted. Self-pay is USD250 for a 30-minute first visit and USD150 for a 15-minute returning visit. Closest comparator in this directory is Stella, which charges USD200/USD90 self-pay. Checked Oct 2026.

Ongoing

Mika (Krebs Therapie Assistent) is a digital health solution, developed by Fosanis GmbH, used for psycho-oncology support, initially ovarian/cervical/endometrial cancer. It is not currently reimbursed in Germany -- WITHDRAWN.

N/A (delisted)

Mindable: Panik & Agoraphobie is a digital therapeutic (DTx), developed by Mindable Health GmbH, used for panic disorder / agoraphobia. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR245.50/90-day Rx (diga.bfarm.de).

Mindable: Soziale Phobie is a digital therapeutic (DTx), developed by Mindable Health GmbH, used for social phobia. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR765.00/90-day Rx (diga.bfarm.de).

Minddistrict is a blended e-mental-health platform, developed by Minddistrict B.V. (Amsterdam, Netherlands; founded 2008), used by Dutch GGZ (mental health and addiction care) providers to deliver online modules, care plans and questionnaires alongside standard therapy for conditions including depression, anxiety and addiction. Described as the market leader in e-mental health in the Netherlands, it has no dedicated digital-therapeutics reimbursement code of its own -- it is billed as part of the standard GGZ treatment course it supports, reimbursed under the same general Zvw basic health insurance rules as that underlying care.

Ongoing -- part of a standard GGZ treatment course

MindDoc Auf Rezept is a digital health solution, developed by MindDoc Health GmbH, used for depression. It is not currently reimbursed in Germany -- WITHDRAWN by MindDoc's own decision.

N/A (delisted)

MindDoc: Psychotherapie per Video is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by MindDoc Health GmbH (a Schön Klinik online offering since 2015, effectiveness researched with LMU Munich), used for depression, eating disorders, anxiety disorders, obsessive-compulsive disorder. Initial diagnostic assessment at one of 200+ partner practices nationwide, then a fixed weekly video therapy slot with a licensed psychotherapist (full outpatient behavioural therapy, not just self-help content), plus a crisis hotline and access...

Not fixed (ongoing outpatient psychotherapy; duration set by clinical need)

MiniMed 780G is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (Guardian 4 or Simplera Sync), with the SmartGuard algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

mom2be is a digital prevention programme, developed by mom2be, used for online courses covering pregnancy and the postpartum period (Beckenbodentraining, Pilates, Yoga). It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Von den gesetzlichen Krankenkassen gefoerderte, zertifizierte Online-Kurse nach Sec.20 SGB V.

MoovCare Poumon is a digital therapeutic, developed by Sivan France, used for post-treatment follow-up for lung cancer patients -- early detection of relapse and complications via a weekly web-based patient symptom questionnaire, analysed by an algorithm that alerts the care team. Listed on France's LPP (reimbursable products list) since a 2019 CNEDiMTS opinion (Service Rendu Suffisant, ASA level III/moderate).

moveUp is a remote-monitoring / digital health platform, developed by moveUP NV, used for multi-domain digital care platform, NOT heart-failure-specific. Per the product's own mHealthBELGIUM listing: orthopaedics (arthroplasty and conservative treatment), cardiology (surgery and heart failure), oncology (haematology), abdominal surgery, obesity, respiratory (COPD, asthma) and neurology; personalised care plans, education and monitoring tools across all of these. It is reimbursed nationally in Belgium.

MOVEVO App is a digital prevention programme, developed by Movevo Technologies GmbH, used for general workplace movement and physical-activity motivation. Not indication-specific. It is offered in Austria as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

My Dose Coach is a digital health solution, developed by METEDA s.r.l. (Italy); marketed in Germany by Sanofi, used for type 2 diabetes on long-acting basal insulin (or basal insulin + GLP-1 fixed combination). Physician sets a dosing plan via a portal, patient logs fasting blood glucose and receives daily insulin-dose guidance. It is not currently reimbursed in Germany -- Delisted.

N/A (delisted)

My7steps App is a digital therapeutic (DTx), developed by My7steps gGmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR207.00/60-day Rx (diga.bfarm.de).

myCOPD is a digital therapeutic, developed by My mHealth Limited, used for cOPD self-management -- digital pulmonary rehabilitation, symptom tracking, inhaler-technique training, education and medication support, with clinician communication. Formally recognised in two NICE Early Value Assessments (HTE18 for pulmonary rehabilitation, HTE19 for broader self-management), giving conditional NHS commissioning approval until December 2027 while further outcomes evidence is generated.

myDiabby Healthcare is a French diabetes-monitoring platform. Patients record blood-glucose readings in the app and the data reaches the diabetology team through a clinician-facing web dashboard, so follow-up during pregnancy can run between appointments instead of only at them. France reimburses the gestational-diabetes indication through a product-specific code on the telemonitoring list; the same platform is also used outside that indication, which is not covered by this listing.

Duration of the pregnancy

mylife YpsoPump mit CamAPS FX is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (Abbott FreeStyle Libre 3 or Dexcom G6), with the CamAPS FX (CamDiab) algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

MyMEDIAN@Home is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by MEDIAN Kliniken (major German rehabilitation-clinic operator group; in-house developed), used for all somatic rehabilitation conditions (24 training/wellbeing/knowledge modules) plus a dedicated neurological track (36 modules). It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Up to 12 months post-rehab

mymobility (Zimmer Biomet) is a remote-monitoring / digital health platform, developed by Zimmer Biomet Holdings, Inc., used for hip and knee replacement (joint arthroplasty) perioperative care management. Pre/post-op education, PROMs, and passive step-count/mobility tracking via a connected Apple Watch, feeding a surgeon-facing dashboard. It is reimbursed nationally in the USA via Medicare's Remote Therapeutic Monitoring CPT codes (98975-98981). Live -- widely deployed across US orthopaedic practices using Zimmer Biomet hip/knee implants -- App is free for the patient; the enrolling...

myReha is a digital therapeutic (DTx), developed by nyra health GmbH (Vienna, Austria, founded 2020; founders Moritz Schöllauf, Mario Zusag, Philipp Schöllauf; EUR20m Series A), used for speech, cognition, memory and everyday-skills therapy for neurological conditions: aphasia, stroke, traumatic brain injury, dementia; 65,000+ adaptive exercises. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

6 months (per licence)

myReha (DRV Reha-Nachsorge) is a digital therapeutic (DTx), developed by nyra health GmbH (Vienna, Austria, founded 2020; founders Moritz Schöllauf, Mario Zusag, Philipp Schöllauf; EUR20m Series A), used for same speech, cognition, memory and everyday-skills therapy for neurological conditions (aphasia, stroke, traumatic brain injury, dementia, Parkinson's, MS) as the GKV-Selektivvertrag offering, delivered as DRV-funded post-rehab aftercare instead. ~50,000 patients across 100+ clinics, ~98% satisfaction reported in a DRV pilot. It is reimbursed in Germany through the statutory...

Not fixed (duration tied to individual DRV aftercare period)

myWEIGHTcoach / myHEALTHcoach is a digital prevention programme, developed by ESG, used for 8-week digital nutrition and weight-management courses (myWEIGHTcoach for weight loss, myHEALTHcoach for general healthy eating) offered through multiple statutory insurers. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). ZPP-zertifiziert nach Sec.20 SGB V; EUR89, 71-89% Erstattung je nach Krankenkasse; gelistet u.a. bei KKH, Novitas-BKK, meine krankenkasse.

8 weeks

Nacken-Athlet / MOBIFIT / Stickletics is a digital prevention programme, developed by Ramin Waraghai, used for neck/shoulder strength (Nacken-Athlet), mobility (MOBIFIT) and pole training (Stickletics). Movement-based online prevention courses by DSHS-Koeln-credentialed trainer Ramin Waraghai, hosted on gesundheitskurs.de. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). ZPP-zertifiziert nach Sec.20 SGB V; EUR119, bis zu 100% Erstattung durch die gesetzliche Krankenkasse.

neolexon Aphasie is a digital therapeutic (DTx), developed by neolexon GmbH (formerly Limedix GmbH), used for aphasia (post-stroke). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR223.01/90-day Rx (diga.bfarm.de).

neolexon Aphasie-App is a digital therapeutic (DTx), developed by neolexon GmbH, used for aphasia therapy. Home-training app for adults with aphasia (post-stroke or other acquired brain injury), used to supplement, not replace, in-person speech-language-pathology (Logopädie) sessions. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (ongoing supplement to in-person speech therapy)

neolexon Artikulations-App is a digital therapeutic (DTx), developed by neolexon GmbH, used for articulation-disorder home-training app for children aged 3-7 already in speech-language-pathology (Logopädie) treatment; used to supplement, not replace, in-person SLP sessions. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

3 or 6 months (licence; pricing scales with duration)

neotivCare is a remote-monitoring / digital health platform, used for 3 validated cognitive/memory tests over 12 weeks, tablet/smartphone-based, distinguishes age-related from disease-related memory decline. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 weeks (3 cognitive/memory tests)

NeuroNation MED is a digital therapeutic (DTx), developed by Synaptikon GmbH, used for mild cognitive impairment. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR229.00/90-day Rx (diga.bfarm.de).

Newcard is a remote-monitoring / digital health platform, developed by Newcard, used for cardiac remote monitoring. It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

Nia is a digital therapeutic (DTx), developed by Nia Health GmbH (Berlin; spun out of Charite Berlin, 2019; partnered with Sanofi/Sanofi Genzyme), used for atopic dermatitis / neurodermitis (ICD L20). AI-based skin-condition documentation, flare-trigger identification, personalised recommendations, follows the AGNES neurodermitis-training curriculum. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

6 or 12 months (package-dependent -- 'Digitale Begleitung' vs 'Tagebuch PLUS')

NichtraucherHelden-App is a digital therapeutic (DTx), developed by NichtraucherHelden GmbH, used for smoking cessation. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR211.00/90-day Rx (diga.bfarm.de).

NielsApp (Mein Kunstgelenk) is a hospital patient-information and care-pathway companion app, developed by Niels-Stensen-Kliniken GmbH, used for perioperative patient information for hip and knee joint replacement surgery at Niels-Stensen-Kliniken. It is provided free in Germany by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any insurer, employer or the patient.

NightWatch+ detects motor epileptic seizures during sleep and alerts carers. A wireless sensor worn on the arm continuously monitors heart rate (photoplethysmography), movement and body position (3D accelerometer); when a potentially dangerous seizure is detected the sensor signals a separate alarm station. It is intended for people aged 4 and over with diagnosed epilepsy and nocturnal motor seizures, living at home or in assisted-living settings, and alarms can be forwarded to nurse call systems. The NightWatch Portal, included free of charge, lets carers review detailed sensor data after the fact -- the course of the night and why an alarm fired. The detection algorithm was developed by the Dutch TeleEpilepsy Consortium and validated against manual video review in multicentre home-setting trials: median sensitivity for the main motor seizure types was 86% in adults and 100% in children, rising to 96% and 100% for tonic-clonic seizures specifically, at a mean false-alarm rate of 0.04 per hour. In Germany it is reimbursed as a Hilfsmittel under § 33 SGB V.

Continuous nightly use for as long as the indication persists

nilo is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Likenilo GmbH (trading as nilo; formerly Nilo Health, merged with Likeminded Feb 2025), used for mental health. Stress, burnout prevention, and general psychological wellbeing support for employees and managers. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Noctua Care is a digital therapeutic, developed by Noctua Care SAS (Paris, France) with cardiologists, used for coronary artery disease -- after a heart attack, acute coronary syndrome, stent or bypass, and in stable disease. It runs a twelve-week guided secondary-prevention programme across five areas: stress and sleep, movement, nutrition, medication adherence and personalised planning, with daily action plans, an AI chat for questions, tracking of appointments, medications and readings, and guided meditation and exercise sessions. The company states the programme follows European Society of Cardiology secondary-prevention guidance, and describes it on its German site as a CE-marked Class I medical device under MDR 2017/745. It is free for patients and not nationally reimbursed in France, reaching them instead through clinical and patient-side partners -- CHU de Bordeaux, the College National des Cardiologues des Hopitaux and Alliance du Coeur. A German market entry is in preparation and a US launch is announced as coming soon.

Noona is a remote-monitoring / digital health platform, developed by Varian Medical Systems Belgium (Siemens Healthineers group), used for oncology patient-reported outcomes. Symptom tracking and secure messaging with the cancer care team during treatment, recovery and post-treatment care. It is reimbursed nationally in Belgium.

Novego: Ängste überwinden is a digital therapeutic (DTx), developed by IVPNetworks GmbH, used for anxiety disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (one-off licence); manufacturer price EUR189.00 one-off licence (diga-verzeichnis.de).

Novego: Depressionen bewältigen is a digital therapeutic (DTx), developed by IVPNetworks GmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (one-off licence); manufacturer price EUR199.00 one-off licence (diga-verzeichnis.de).

Novio Hand is a digital therapeutic (DTx), developed by LIME medical GmbH (Mainz, Germany) in partnership with Bauerfeind, used for hand injuries and degenerative hand conditions in postoperative or post-treatment rehabilitation. Delivers dynamically-adjusted, feedback-guided exercise training intended to improve range of motion, hand function and pain. Its current market/reimbursement status is unclear from public sources -- a registered RCT (DRKS00033768) is comparing it to standard aftercare, but no confirmed DiGA listing or public self-pay purchase option was found, unlike its sibling product Novio Rücken (back pain), which is already a reimbursed DiGA.

Novio Rücken is a digital therapeutic (DTx), developed by LIME medical GmbH (Mainz, Germany) in partnership with Bauerfeind, used for nonspecific back pain in patients aged 16 and older. LIME medical states it is reimbursed 100% by statutory health insurance with no co-payment, and that many private insurers reimburse fully or largely. However, Novio Rücken does not appear anywhere in BfArM's official DiGA-Verzeichnis as of this research (checked including the delisted/"Gestrichen" filter), so the reimbursement claim could not be independently verified.

Nukkuaa (aka sleep(2)) is a digital therapeutic (DTx), developed by Nukkuaa GmbH (Salzburg, Austria, founded 2022; spin-off of Paris-Lodron-Universität Salzburg; founders Prof. Manuel Schabus and Dr. Thomas Winkler), used for insomnia / sleep-quality improvement. Overnight heart-rate sensor (Polar strap or Apple Health/Google Fit) + algorithmic sleep-stage analysis + evidence-based sleep training. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 months (1 year, free for TK-insured)

Odysight is a mobile application from Tilak Healthcare that lets people with a chronic retinal condition test their own vision at home between hospital appointments. The visual tests are embedded in a casual puzzle game, which is the design idea behind the product: the measurement happens as a by-product of play rather than as a chore. Results go to the treating ophthalmologist through a web platform, so a deterioration can bring an appointment forward instead of waiting for the next scheduled visit. France reimburses it through the early-access PECAN scheme rather than the permanent list.

Ongoing, reassessed at renewal

Okeiro (formerly Predict4Health, renamed per company LinkedIn) is a remote-monitoring / digital health platform, developed by Okeiro, used for cardiac & renal deterioration prediction (AI). It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

Omada Cardiometabolic Suite (Prevention, Diabetes, Hypertension, GLP-1 support) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Omada Health, Inc., used for prediabetes, type 1 & 2 diabetes, hypertension, and support for members on GLP-1/anti-obesity medications. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Omada for Joint & Muscle Health is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Omada Health, Inc., used for musculoskeletal pain. Joint and muscle conditions. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Omnipod 5 is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (Dexcom G6 or G7), with the SmartAdjust algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

Online-Hautcheck (OnlineDoctor) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by OnlineDoctor AG, used for skin conditions / suspicious moles. Asynchronous photo-based dermatology consultation. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

onyo is a digital prevention programme, developed by onyo GmbH, used for home-office/remote-work ergonomics and statutory workplace risk assessment. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

OpenUp is an employer-funded mental well-being platform for the workplace, positioned by the company as "a modern EAP". Employees of subscribing organisations can book 1:1 sessions with psychologists, and the service extends to lifestyle and financial coaching, group sessions and self-guided material, with a 24/7 support line included. The company reports 600,000+ employees across 2,000+ organisations and support in 45 languages, and states that sessions require no referral or approval. In the Netherlands this sits entirely outside the Zorgverzekeringswet: the employer pays, so there is no deductible (eigen risico) and no GP/POH-GGZ gatekeeping -- but equally no coverage for anyone whose employer does not subscribe. OpenUp is not a medical device; its ISMS is certified to ISO 27001 and NEN 7510.

Ongoing access while the employer subscribes

ORIKO ADHS-Therapie is a digital therapeutic (DTx), developed by Oriko GmbH, used for ADHD (adults). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR360.00/90-day Rx (diga.bfarm.de).

Orthopy bei Knieverletzungen is a digital health solution, developed by Orthopy Health GmbH, used for knee injuries / rehabilitation. It is not currently reimbursed in Germany -- WITHDRAWN 9 Sep 2025. Since its September 2023 launch, it has been marketed in Germany via an exclusive distribution/marketing partnership with Enovis, a global orthopedics/medtech company ("Orthopy powered by Enovis"); Enovis handles sales and marketing while Orthopy Health GmbH retains product development and medical content.

N/A (delisted)

Oshi Health is a virtual multidisciplinary GI clinic covering IBS, Crohn's disease, ulcerative colitis, GERD, SIBO and undiagnosed GI symptoms, combining gastroenterology care with dietitians and gut-brain specialists. The company states it is in-network with most major health plans, so that many patients pay little to nothing out of pocket depending on plan, and that it is not in-network with Medicare or Medicaid; remaining out-of-pocket costs can be spread over payment plans and the services are HSA-eligible. Unlike the other virtual clinics recorded here it runs three channels at once -- direct to patient, employer partnerships and value-based contracts with health plans. Checked Oct 2026.

Ongoing

OsteoCoach is a mobile app for people aged 65 and over whose fear of falling limits everyday life. Its stated intended purpose, taken from the electronic instructions for use (QBM-OSTEOCOACH-IFU-001 of 25 Feb 2026), is "Software zur Verringerung des Sturzrisikos bei Personen ab 65 Jahren": a guided entry test records physical fitness and fall-related anxiety, from which the app builds a personalised modular training programme aimed at improving strength and balance and reducing fear of falling. Four modules are offered -- Fitness, Mental, Tai Chi and Wissen (knowledge). The company says its clinical pilot study is complete and evaluated but that the results are not yet published, and that the app holds a BSI TR-03161 certificate for version 1.1.0. It is a medical device pursuing DiGA listing under § 139e SGB V; the BfArM application was in preparation as of October 2026. Note three company names appear around the product: Osteoconnect GmbH (Berlin) operates the site, QuickBird Market GmbH (Munich) is named as manufacturer in the instructions for use, and the App Store seller is OSTEOCONNECT IP LTD.

Self-paced, no fixed programme length

Oviva Direkt Bluthochdruck is a digital therapeutic (DTx), developed by Oviva AG, used for hypertension. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR599.00/90-day Rx (diga.bfarm.de).

Oviva Direkt für Adipositas is a digital therapeutic (DTx), developed by Oviva AG, used for obesity. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR243.00/90-day Rx (diga-verzeichnis.de).

OvulaRing is a remote-monitoring / digital health platform, used for cycle/ovulation tracking for women with irregular menstruation or unfulfilled desire to have children. Wearable vaginal-ring hormone sensor + companion app; NOTE: this is hardware + app, closer to the RPM/telemonitoring category than a pure software DTx, included here because its reimbursement mechanism (per-insurer Kostenerstattung) matches this sheet's other entries. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

12 months (annual reimbursement cap, renewable)

Patient Journey App (platform) is a hospital patient-information and care-pathway companion app, developed by Patient Journey App, used for perioperative and general hospital-stay information across surgical and non-surgical care pathways, department- and procedure-configurable per hospital. It is provided free in Germany by the treating hospital or device manufacturer as part of the care episode itself -- not billed to any insurer, employer or the patient.

Paula-App is a digital therapeutic (DTx), developed by Endo Health GmbH (Chemnitz, Germany, founded 2020 as Endo Health UG by Nadine Rohloff), used for polycystic ovary syndrome (PCOS). A multimodal self-management companion (symptom diary, learning modules from psychology, nutrition and physiotherapy, interactive exercises) addressing cycle irregularity, fertility concerns, hirsutism, weight management and psychological burden. It is a CE-marked medical device, free to download, but not yet listed in BfArM's DiGA directory. Endo Health reports that a randomized study with over 200 participants is evaluating the app, with results expected in Q3 2025; this has not been published, so the claim could not be independently verified.

PBC Begleiter supports people living with primary biliary cholangitis (PBC) in managing the condition day to day, with the stated aim of strengthening disease literacy and active self-management. It was co-developed with PBC patients. Users who consent can log symptoms, test results and quality of life; those data are analysed anonymously by Prof. Dr. Dr. Andreas Teufel (Greifswald) so that care gaps and the burden of PBC can be published and put before health policymakers -- the company states the documentation is anonymous with no possibility of tracing it back, and GDPR-compliant. A patient advisory board can propose questions for future analyses. The app is free; it is funded by Ipsen Pharma GmbH, so no payer reimburses it. Project lead is the non-profit Kautz5 gUG (Cologne); the software was built by Quickbird Medical GmbH (Munich).

Ongoing use, no fixed programme length

Peppy is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Peppy Health Ltd., used for menopause, fertility, and men's health (including prostate and mental health). Specialist life-stage health support for employees. It is offered in the United Kingdom as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Personify Health is a digital prevention programme, developed by Personify Health, Inc. (formerly Virgin Pulse + HealthComp), used for general employee wellbeing, health-plan navigation and personalised health journeys. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Pia-App bei Regelschmerzen is a digital therapeutic (DTx), developed by Endo Health GmbH (Chemnitz, Germany, founded 2020 as Endo Health UG by Nadine Rohloff), used for menstrual pain (primary dysmenorrhea, ICD-10 N94.4). A multimodal self-management companion (symptom diary, learning modules from medicine, physiotherapy, nutrition and pain management, guided in-app exercises, SOS list). It is reimbursed nationally in Germany via the DiGA (provisional) pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR598.95/90-day Rx, no extra costs (diga.bfarm.de).

PINK! Coach is a digital therapeutic (DTx), developed by PINK! gegen Brustkrebs GmbH, used for breast cancer (psycho-oncology). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR234.50/90-day Rx (diga.bfarm.de).

Plateforme Maela is a remote-monitoring / digital health platform, developed by Medtronic Belgium (Medtronic plc), used for multi-specialty surgical patient engagement and monitoring. Configurable digital care protocols for colorectal, bariatric, spine, AFS and thoracic surgery pathways, among others. It is reimbursed nationally in Belgium.

platoniq is a digital prevention programme, developed by SHS Social Health Solutions UG (Berlin) under the brand platoniq, used for loneliness and stress. It treats social support as the central coping resource and works on it with methods from cognitive behavioural therapy: building and maintaining a network, recognising and changing unhelpful thinking about one's social life, and integrated relaxation exercises. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway as a ZPP-certified course (ID KU-ST-RB7DXE), priced at EUR99 for six weeks and 61 units, with reimbursement claimed after 49 units are completed. It was developed with psychologists at Humboldt-Universität zu Berlin and co-financed by Berlin and the European Union.

6 weeks (61 units)

Poppins Clinical is a digital therapeutic (DTx), developed by BMOTION Technologies (brand: Poppins; formerly Mila until Oct 2023), used for dyslexia and related learning disorders, children 7-11. It is reimbursed nationally in France via the PECAN pathway. PECAN tariff: EUR435 flat fee first 3 months, then EUR38.30/month, max EUR780/yr. The arrete was published in the Journal Officiel on 21 Jul 2026 and reimbursement took effect on 3 Aug 2026.

Prevencer is a digital prevention programme, developed by Prevencer, used for krafttraining ohne Geraete. Equipment-free strength-training online prevention course. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). ZPP-zertifizierter Online-Praeventionskurs nach Sec.20 SGB V; bis zu 100% Kostenerstattung durch die gesetzliche Krankenkasse.

Prevenio (R) is a digital prevention programme, developed by TransGate GmbH, used for statutory occupational-medical fitness/eligibility examinations and preventive check-ups. Administrative/compliance tool, not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Preventicus Heartbeats is a digital prevention programme, developed by Preventicus GmbH, used for atrial fibrillation screening (stroke prevention), insured persons 55+. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

priovi is a digital therapeutic (DTx), developed by GAIA AG, used for borderline personality disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR244.00/90-day Rx (diga.bfarm.de).

ProHerz is a digital therapeutic (DTx), developed by ProCarement GmbH, used for heart failure. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR235.00/90-day Rx (diga.bfarm.de).

Prothera Fit is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, used for multimodal and training-therapy digital rehabilitation aftercare, prevention and rehabilitation content (app-based, iOS/Android); specific indication breadth not independently itemised in this pass. It is reimbursed in Germany through the statutory pension/care-insurance system rather than standard health insurance.

Not fixed (duration tied to individual DRV aftercare period)

re.flex is a digital health solution, developed by Kineto Tech Rehab SRL (Romania), used for knee osteoarthritis (gonarthrosis). Sports/movement therapy, developed with Sporlastic Medizinische Produkte GmbH. It is not currently reimbursed in Germany -- Delisted.

N/A (delisted)

Rejoyn is a digital therapeutic (DTx), developed by Otsuka Precision Health / Click Therapeutics, used for major depressive disorder (adjunct, ages 22+). It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Medicare-billable since 1 Jan 2025; broader commercial-payer coverage NOT confirmed -- Billed by the prescribing clinician: G0552 + G0553/G0554; as of Apr 2025 no commercial insurer publicly confirmed on board -- still largely self-pay/discounted cash (~$50) or Medicare-billed only.

RelieVRx is an FDA-authorized virtual-reality digital therapeutic, developed by AppliedVR, Inc. (Los Angeles, CA), used for chronic lower back pain. It delivers an 8-week program of cognitive-behavioral and pain-education skills through an immersive VR headset. Authorized by the FDA via the De Novo pathway in Nov 2021, it became the first VR therapeutic to receive its own Medicare billing code when CMS assigned HCPCS Level II code E1905 (effective Apr 2023), classified as Durable Medical Equipment. CMS has not yet finalized the payment rate for this code, so real-world coverage remains uneven and payer-dependent in the meantime.

8-week program (skills-based sessions)

Remecare is a remote-monitoring / digital health platform, developed by Newexo / Remecare, used for chronic heart failure remote monitoring & coaching. It is reimbursed nationally in Belgium.

Remi Health (HPV-Heimtest) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Remi Health GmbH (myremi.com), used for cervical cancer screening. At-home HPV self-sampling kit (tests HPV 16, HPV 18 plus 12 further high-risk types), digital result delivery, and telephone consultation with a Remi-network gynaecologist for abnormal results. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

One-time screening (not an ongoing programme)

reSET is a digital therapeutic (DTx), developed by PursueCare (acquired Pear Therapeutics' reSET/reSET-O assets, 2023), used for substance use disorder. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 (Medicare); commercial coverage via Cigna PDT policy -- Billed by the prescribing clinician: G0552 + G0553/G0554.

reset U is a digital prevention programme, developed by reset U, used for online courses for burnout prevention and depression prevention. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifiziert nach Sec.20 SGB V (ZPP); EUR99, 79-99% Erstattung durch die gesetzliche Krankenkasse.

reSET-O is a digital therapeutic (DTx), developed by PursueCare (acquired Pear Therapeutics' reSET/reSET-O assets, 2023), used for opioid use disorder. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 (Medicare); commercial coverage via Cigna PDT policy -- Billed by the prescribing clinician: G0552 + G0553/G0554.

RESILIENCE PRO is a remote-monitoring / digital health platform, developed by Resilience, used for oncology remote monitoring and supportive care. Helps patients cope with treatment side effects and improves quality of life during and after cancer treatment. It is reimbursed nationally in France via the PECAN pathway. Reimbursed under the French telesurveillance framework since Oct 2023; exact CEPS tariff not independently confirmed in this pass.

RESILIENCE PRO is a remote-monitoring / digital health platform, developed by Resilience, used for oncology remote monitoring and supportive care. Helps patients cope with treatment side effects and improves quality of life during and after cancer treatment. It is reimbursed nationally in Belgium.

SaniQ HERZ is a connected medical device (with companion software), developed by Qurasoft GmbH, used for chronic heart failure remote monitoring (external measurement devices). It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since Jan 2022 (G-BA resolution 2020).

Sanum Entspannungskurs is a digital prevention programme, developed by Sanum, used for online audio-guided relaxation and stress-management course, 8 sessions of 45 minutes each. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifizierter Praeventionskurs (ZPP), entspricht dem Leitfaden Praevention (Sec.20 Abs.1 SGB V); wird von allen gesetzlichen Krankenkassen erstattet; EUR99.

8 x 45 min

Satelia Cardio is a French remote-monitoring service for chronic heart failure. Patients answer a short recurring questionnaire about symptoms and weight; deterioration signals are relayed to the cardiology team so an intervention can happen before a hospital admission. It is one of the few products on the French telemonitoring list to hold a product-specific tariff distinctly higher than the generic rate for the same condition, which is what makes its listing worth reading closely: the French system usually pays one rate per care activity, not per product.

Ongoing

Schlank ohne Diaet is a digital prevention programme, developed by Fitnessdoc.net, used for certified online course for sustainable weight loss without dieting. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifizierter Praeventionskurs nach Sec.20 SGB V; Kosten koennen von der gesetzlichen Krankenkasse uebernommen werden.

Selfapys Online-Kurs bei Binge-Eating-Störung is a digital therapeutic (DTx), developed by Selfapy GmbH, used for binge eating disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR232.00/90-day Rx (diga-verzeichnis.de).

Selfapys Online-Kurs bei Bulimia Nervosa is a digital therapeutic (DTx), developed by Selfapy GmbH, used for bulimia nervosa. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR232.00/90-day Rx (diga.bfarm.de).

Selfapys Online-Kurs bei chronischen Schmerzen is a digital health solution, developed by Selfapy GmbH, used for chronic pain. CBT-based methods and techniques. It is not currently reimbursed in Germany -- WITHDRAWN 28 May 2025.

N/A (delisted)

Selfapys Online-Kurs bei Depression is a digital therapeutic (DTx), developed by Selfapy GmbH, used for depression. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR217.18/90-day Rx (diga.bfarm.de).

Selfapys Online-Kurs bei Generalisierter Angststörung is a digital therapeutic (DTx), developed by Selfapy GmbH, used for generalised anxiety disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR228.50/90-day Rx (diga-verzeichnis.de).

Selfapys Online-Kurs bei Panikstörung is a digital health solution, developed by Selfapy GmbH, used for panic disorder. It is not currently reimbursed in Germany -- WITHDRAWN by end of Sept 2023.

N/A (delisted)

Semeia is a remote-monitoring / digital health platform, developed by Semeia, used for chronic kidney disease remote monitoring. It is reimbursed nationally in France via the PECAN pathway. PECAN: EUR435 first 3 months then EUR38.30/month, max EUR780/yr (standard PECAN telesurveillance tariff, same schedule as Implicity).

SilentCloud is a digital therapeutic (DTx), developed by Aureliym GmbH (Bad Neuenahr-Ahrweiler, Germany; part of the Sonova hearing-care group), used for tinnitus. Combines patient education, validated assessments, internet-based cognitive behavioural therapy (iCBT) and sound therapy on a subscription basis. It is not yet available in Germany -- currently live only in Belgium and Italy -- but has obtained BSI TR-03161 certification, the German cybersecurity prerequisite for DiGA listing, suggesting a German launch may follow.

SilverCloud (Space from Depression / Space from Anxiety) is a digital therapeutic (DTx), developed by SilverCloud Health, used for depression and anxiety/GAD. It is reimbursed nationally in the United Kingdom via the NHS Talking Therapies DET pathway. NHS England DET-compliant, nationally usable within NHS Talking Therapies -- Commissioned locally by individual NHS Talking Therapies services, drawn from NICE's nationally-vetted DET list; NOTE -- distinct from this same company's separate 'SilverCloud - Making Space for Healthy Minds' listing on the 'UK - ORCHA Recommended Apps' tab (a...

sinCephalea Migräneprophylaxe (now marketed via m-sense.de) is a digital therapeutic (DTx), developed by Perfood GmbH (Lübeck, founded 2017 -- same manufacturer as glucura), used for migraine prophylaxis via personalised nutrition, based on continuous glucose monitoring (CGM) + headache diary; RCT with 800+ patients showed significant reduction in monthly migraine days. It is available in Germany on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer. Following withdrawal from the DiGA directory on 22 Jan 2026 the product remains available as a self-pay offer, marketed under the M-sense name: m-sense.de is branded "M-sense by Sincephalea" and is operated by Perfood GmbH, not by Newsenselab, which built the original M-sense app. Former users of that original app have in effect been moved to a different product.

12 weeks (self-pay commercial product; no longer SHI-reimbursed)

Skinapy Akne is a digital therapeutic (DTx), developed by Dermafy Group GmbH (Schorndorf, Germany), used for acne vulgaris. The programme covers nutrition, skin care and cleansing routines, and psychological support for a holistic approach alongside dermatological treatment. Dermafy Group states that statutory health insurers reimburse it 100% on a doctor's prescription (3-month cycle) and private insurers reimburse per individual tariff; a self-pay access code is also sold directly via the manufacturer's own shop. However, Skinapy Akne does not appear anywhere in BfArM's official DiGA-Verzeichnis as of this research (checked including the delisted/"Gestrichen" filter), so the reimbursement claim could not be independently verified.

3-month prescription cycle

Skinuvita is a digital therapeutic (DTx), developed by Skinuvita GmbH (Bremen, founded 2021; backed by High-Tech Gründerfonds and private investors incl. Stefan Bellinger; EUR1.8m raised), used for digital therapy SYSTEM: smart home UV-irradiation device (hardware) + telemonitoring by participating dermatologists. Moves UV phototherapy, previously clinic/practice-only, into the home. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (pilot phase, ongoing)

Skleo Augenvorsorge-Check is an AI-supported preventive eye screening service, operated by Skleo Health GmbH (Düsseldorf), used to look for signs of conditions such as glaucoma and diabetic retinopathy. A retinal image taken at a partner optician or drugstore is analysed by an AI for 12 retinal markers and then validated in every case by a German-licensed ophthalmologist, with a report within 24 hours and, on an abnormal finding, a specialist appointment booked through the platform. The AI is CE-marked as a medical device under MDR class IIa, and the company cites a scientific collaboration with Charité Universitätsmedizin Berlin. It is a self-pay service: not reimbursed, not a §20 prevention course and not a DiGA, though some partner sites are designated insurance partners.

Sleepio is a digital therapeutic (DTx), developed by Big Health, used for insomnia and insomnia symptoms. It is available in the United Kingdom through a regional or time-limited pilot commissioning arrangement, not (yet) an established national or ongoing regional/selective contract.

SleepioRx is a digital therapeutic (DTx), developed by Big Health, used for chronic insomnia. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 -- Billed by the prescribing clinician: G0552 (device supply/onboarding) + G0553/G0554 (monthly treatment-management time, ~$20/20min).

SleepQ (formerly WELT-I) is a digital therapeutic (DTx), developed by WELT Corp (웰트) / Handok (한독, commercial partner), used for chronic insomnia. CBT-i programme. It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

Smoke Free - Rauchen aufhören is a digital therapeutic (DTx), developed by Smoke Free 23 GmbH (parent: 23 Ltd, UK), used for smoking cessation. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR231.25/90-day Rx (diga-verzeichnis.de).

somnio is a digital therapeutic (DTx), developed by mementor DE GmbH, used for insomnia. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR224.99/90-day Rx (diga.bfarm.de).

somnovia is a digital therapeutic (DTx), developed by GAIA AG, used for chronic insomnia. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR236.00/90-day Rx (diga.bfarm.de).

Somryst is a digital therapeutic (DTx), developed by Nox Health (acquired the Somryst asset from Pear Therapeutics' bankruptcy estate), used for chronic insomnia. It is reimbursed nationally in the USA via Medicare's HCPCS G0552-G0554 digital mental health treatment codes. Reimbursed since 1 Jan 2025 (Medicare); added to Serve You Rx/OptumRx pharmacy-benefit formularies for select commercial/self-insured employer plans -- Billed by the prescribing clinician: G0552 + G0553/G0554; formulary listing separately covers the device cost for enrolled plan members.

Somzz is a digital therapeutic (DTx), developed by AIMMED (에임메드), used for chronic insomnia. CBT-i (cognitive behavioural therapy for insomnia) programme. It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

Sooma tDCS is an EU MDR-certified transcranial direct current stimulation (tDCS) device, developed by Sooma Oy (Helsinki, Finland), used for depression and chronic pain via a non-invasive brain-stimulation headset worn for 30-minute sessions, 5 days a week, for a minimum of 4 weeks. It is sold direct-to-patient (self-pay) in Finland and Germany, ordered online with no referral required. Sooma is separately one of 10 companies selected for Finland's DigiFinland pilot (Oct 2025), a government evaluation programme -- the pilot itself carries no reimbursement mechanism yet.

4 weeks minimum (30 min/session, 5 days/week)

SoriCLEAR is a digital therapeutic (DTx), developed by NuLive (뉴라이브), used for tinnitus. It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

Spring is a digital therapeutic (DTx), used for post-traumatic stress disorder (PTSD). It is reimbursed nationally in the United Kingdom via the NHS Talking Therapies DET pathway. NHS England DET-compliant, nationally usable within NHS Talking Therapies -- Commissioned locally by individual NHS Talking Therapies services, drawn from NICE's nationally-vetted DET list.

Stella is a virtual menopause clinic from Vira Health Limited: video visits with board-certified clinicians licensed in all 50 states, prescriptions (including HRT) sent to the patient's pharmacy, plus a companion app with coaching and lifestyle programmes. Reimbursement attaches to the clinician visit, not to a listed product -- Stella states it is in-network with hundreds of commercial plans, naming Aetna, Anthem, BlueCross BlueShield and UnitedHealthcare, with an average copay of about USD45 and coverage varying by plan. Patients without in-network coverage pay USD200 for the initial visit and USD90 per follow-up and receive a superbill to submit themselves. Medications are FDA-regulated and typically run through pharmacy benefits rather than through this service. The company is UK-based and also operates Stella UK (fully private, explicitly not NHS: GBP85 initial appointment plus GBP10 per prescription) and Stella South Africa. Checked Oct 2026.

Ongoing

Sword Bloom is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Sword Health, Inc., used for women's health across every life stage. Incl. pregnancy, postpartum and menopause-related conditions. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Sword Mind is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Sword Health, Inc., used for anxiety, depression and other common mental-health conditions. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Sword Pulse is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Sword Health, Inc., used for cardiometabolic health. E.g. hypertension, high cholesterol, weight-related risk. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Sword Thrive is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Sword Health, Inc., used for musculoskeletal pain. Back, joint, neck, shoulder and repetitive-strain conditions. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

t:slim X2 mit Control-IQ is an automated insulin delivery (AID) system: an insulin pump coupled to a real-time CGM (Dexcom G6 or G7), with the Control-IQ algorithm automatically adjusting the basal rate and delivering automatic correction boluses while leaving manual adjustment available. In Germany it is listed in the Hilfsmittelverzeichnis under § 33 SGB V as "Variante 3" of product types 30.29.05/30.29.06 — the category defined by exactly that combination of automatic basal adjustment and automatic correction boluses — and is supplied nationwide on prescription.

Continuous use for as long as the indication persists

taozen is a digital prevention programme, developed by Tao Zen, used for tai-Chi- and Qigong-based online movement courses (fernoestliche Bewegungslehren) for stress reduction. It is reimbursed nationally in Germany via the §20 SGB V Leitfaden Prävention pathway (ZPP-certified). Zertifiziert nach Sec.20 SGB V (ZPP); Erstattung bis zu 100% durch die gesetzliche Krankenkasse, zweimal jaehrlich bezuschusst.

teamfit is a digital prevention programme, developed by Teamfit GmbH, used for general workplace movement, motivation and vital-sign wellness. Not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

telecor (SHL Telemedizin) is a connected medical device (with companion software), developed by SHL Telemedizin GmbH (part of SHL Group), used for chronic heart failure remote monitoring, TMZ-as-a-service for cardiologists. It is reimbursed nationally in Germany via nationwide EBM remote-monitoring/telemonitoring billing codes. Reimbursed since Jan 2022.

TheraKey (Berlin-Chemie) is a manufacturer-sponsored patient-education and therapy-support platform, developed and funded by Berlin-Chemie AG (Berlin, Germany; part of the Menarini Group), launched in 2012, used for patient education and therapy support across 8 chronic conditions including Type 1/Type 2 diabetes, hypertension, COPD, asthma, angina pectoris, dyslipidemia, gout and premature ejaculation. Unlike this dataset's other entries, funding comes from the drug manufacturer directly, rather than a statutory health insurer or employer.

Thieme TeleCare (Thieme TeleCoach App) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Thieme TeleCare GmbH (subsidiary of the Thieme Verlagsgruppe medical-publishing group; telemedicine coaching provider active since 2000, company states 75,000+ people supported to date), used for multi-condition telemedical coaching: respiratory disease, hypertension/heart health, Long Covid/fatigue, diabetes, overweight, chronic pain, mental health/stress, sleep and more. It is reimbursed in Germany through regional or...

TK-Doc is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Techniker Krankenkasse (TK) -- operated in-house, not a separate vendor company, used for general/primary-care consultation via live chat or phone, in lieu of a waiting-room visit. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Una Health fuer Diabetes is a digital therapeutic (DTx), developed by Una Health GmbH, used for type 2 diabetes. It is not currently reimbursed in Germany -- struck from the DiGA directory on 28 Sep 2026 via a Hamburg regional social court order (Landessozialgericht Hamburg), the second delisting of 2026 after an earlier evidence-deadline strike (30 Mar 2026) was reversed on 22 Jun 2026.

Unmind is a digital prevention programme, developed by Unmind Ltd., used for workplace mental health. Stress, anxiety, depression, sleep and general psychological wellbeing -- not indication-specific. It is offered in the United Kingdom as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Untire(R) is a digital therapeutic (DTx), developed by Tired of Cancer B.V. (Untire), used for breast cancer-related fatigue (ICD-10 C50). It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR240.50/90-day Rx (diga.bfarm.de).

Uroletics is a digital therapeutic (DTx), developed by Rocketlane Medical Ventures GmbH (majority stake acquired by APOGEPHA Arzneimittel GmbH, Dec 2022), used for pre- and post-operative care for prostate surgery. 3D pelvic-floor training, mental-coaching content for surgery preparation and coping, and validated patient information, aimed at preventing/treating post-operative incontinence and erectile dysfunction. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

Not specified (ongoing access under the active Barmenia PKV contract)

Vantage Fit is a digital prevention programme, developed by Vantage Circle (Intellicorp Consulting Pvt. Ltd.), used for general fitness tracking, mood, heart-rate and workout gamification. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

velibra is a digital therapeutic (DTx), developed by GAIA AG, used for anxiety disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR230.00/90-day Rx (diga.bfarm.de).

Vera-App für Wechseljahresbeschwerden is a digital therapeutic (DTx), developed by Endo Health GmbH, used for menopause symptoms. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA (provisional); manufacturer price EUR598.95/90-day Rx (diga-verzeichnis.de).

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

Vertidisan (VH90D) is a 90-day sensorimotor exercise therapy for vestibular vertigo, delivered as a mobile app and used daily at home. It is published by Digitineers GmbH & Co. KG in Tübingen and sold directly as a paid activation code rather than through any listing. Notably, it holds BSI TR-03161 -- the security certification German DiGA listing requires -- without being listed as a DiGA or stating an intention to apply.

90 exercise days; the activation code stays valid for 180 days

viatolea is a digital therapeutic (DTx), developed by PYRA MEDI GmbH (Nuremberg, Germany, founded 2024), used for food intolerances (fructose, sorbitol, lactose, wheat sensitivity). A digital nutrition journal plus an algorithm identifies likely intolerances from logged meals/symptoms and guides users through guideline-compliant dietary changes over a 10-week programme. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

10-week programme

Vigo is a digital therapeutic (DTx), developed by Vigo Health, used for post-stroke rehabilitation (multimodal: physical therapy, activities-of-daily-living guidance, CBT-based tools), for patients who have not entirely lost cognitive ability. It is currently self-pay only (approx. EUR49/month per Latvian press coverage). Vigo has obtained an NVD (National Health Service) manipulation-list code. Uncertain / not independently confirmed for 2025-2026 -- see note above.

Vila RaVie is a digital therapeutic (DTx), developed by Vila Health GmbH (Berlin, Germany), used for inflammatory rheumatic diseases including rheumatoid arthritis (ICD-10 M05/M06), psoriatic arthropathy (L40.5) and systemic lupus erythematosus (M32), targeting disease-related psychological burden and quality of life rather than the underlying disease activity itself. A 12-week, browser-based cognitive-behavioural-therapy programme (no app installation required) covering self-image, daily life, thoughts/feelings, body/symptoms, family/friends, acceptance and health empowerment, guided by a psychotherapist persona. It is currently available in Germany only on a self-pay basis (EUR 149 for a 12-week access code); not yet DiGA-listed. Vila Health reports that effectiveness in reducing psychological burden and improving quality of life was shown in a randomized controlled trial led by the University Hospital Giessen and Marburg (UKGM); this has not been published, so the claim could not be independently verified.

12-week programme

Virdio Health is a digital therapeutic (DTx), developed by Virdio Health, Inc. (Vienna, Virginia, USA, founded April 2019 by Arjun Rishi and Ty Bordner), used for musculoskeletal (MSK) pain such as back, hip and knee pain. Delivered as "Myra", a conversational AI recovery coach accessible from any browser (no app download, no equipment) that builds a personalized recovery program through open-ended dialogue rather than tap-through intake forms, and adapts the plan as the user's condition changes. It is offered as a self-funded-employer benefit at a flat $99 all-in cost per engaged employee (the company also cites "sub $1 PEPM" pricing), with no co-pays or scheduled appointments. Virdio Health reports a 24x return on investment for employers and that 73% of members report significant pain reduction; these are company-reported figures with no independent citation found.

Vitadio is a digital therapeutic (DTx), developed by Vitadio, used for type 2 diabetes. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR224.01/90-day Rx (diga.bfarm.de).

VIVID Brain is a digital therapeutic (DTx), developed by Nunaps (뉴냅스), used for hemianopia (visual field loss following brain lesion/stroke). Cognitive/visual-perceptual training. It is available in South Korea on a self-pay basis -- a reimbursement-eligible pathway may exist, but the patient currently pays out of pocket rather than an insurer or employer.

Vivira is a digital therapeutic (DTx), developed by Vivira Health Lab GmbH, used for back pain. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR206.79/90-day Rx (diga.bfarm.de).

vorvida is a digital therapeutic (DTx), developed by GAIA AG, used for alcohol use disorder. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR185.00/90-day Rx (diga.bfarm.de).

Wellhub (formerly Gympass) is a digital prevention programme, developed by Wellhub, Inc. (formerly Gympass), used for general fitness, mental wellness, nutrition and sleep. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

Wellnow -- Smart Corporate Health is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Wellnow Health GmbH, used for general workplace physical and mental wellbeing. On-site massage, physiotherapy, yoga, back-training, mindfulness -- not indication-specific. It is offered in Germany as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

WellSteps is a digital prevention programme, developed by WellSteps, LLC, used for general wellness behavior change across six health pillars. Not indication-specific. It is offered in the USA as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

WundFit is a digital therapeutic (DTx), developed by 4L Health GmbH (Karlsruhe, Germany), used for chronic wounds such as diabetic, venous or arterial circulatory-disorder wounds. A patient-education and daily-routine companion (structured diary, guided instructions, reminders) intended to strengthen patients' active role in wound self-care alongside clinical treatment. It is currently free to use for participants in the company's clinical study, which is preparatory to a planned DiGA submission; not yet self-pay or DiGA-listed. A Class IIa medical device.

Xinjing Technology VR Insomnia-Disorder Therapy Software (心景科技) is a connected medical device (with companion software), developed by Xinjing Technology (心景科技), used for insomnia disorder. VR-based cognitive-behavioural/relaxation therapy. It is billable in China (Hainan province) under a provincial fee-schedule, not yet nationwide health insurance.

YoniCare (Micado) is a blended-care digital health programme, combining software with ongoing clinician or coach involvement, developed by Micado Health Care GmbH (Hamburg, founded 13 Aug 2004), used for genitourinary syndrome of menopause (GSM). Vaginal dryness, tissue/mucosal changes, itching, incontinence and recurrent UTIs from declining oestrogen; laser therapy revitalises the vaginal epithelium, typically 1-3 sessions 4-8 weeks apart, hormone-free. It is reimbursed in Germany through regional or insurer-specific contracts rather than a nationwide scheme.

1-3 sessions, spaced 4-8 weeks apart

YuMuuv is a digital prevention programme, developed by YuMuuv OU, used for general team fitness and step/activity challenges. Not indication-specific. It is offered in Estonia as an employer-sponsored corporate-health benefit, paid for by the employer or health plan rather than a statutory or private insurer.

zanadio is a digital therapeutic (DTx), developed by aidhere GmbH, used for obesity. It is reimbursed nationally in Germany via the DiGA §139e SGB V pathway. SHI-reimbursed, DiGA; manufacturer price EUR218.00/90-day Rx (diga.bfarm.de).

Zio XT is a digital therapeutic, developed by iRhythm Technologies, Inc., used for ambulatory ECG monitoring (>24 hours) for people with suspected cardiac arrhythmias -- wearable single-lead ECG patch, algorithmic analysis, and clinician report. NICE Medical Technologies Guidance MTG52 recommends Zio XT as an option for ambulatory ECG monitoring beyond 24 hours, replacing standard Holter monitors in eligible NHS pathways.